

CURRICULUM VITAE

NAME: Abraham G. Hartzema

ACADEMIC ADDRESS: Department of Pharmaceutical Outcomes and Policy
1225 Center Drive
HPNP 4304, Health Science Center
PO Box 100496, University of Florida
Gainesville, FL 32610-0496

HOME ADDRESS: 4305 SW 83rd Way
Gainesville, FL 32608

Pharmacy Practice
PHONE: (352) 273-6223 - office
(352) 871-1839 - cell

FAX: (352) 273-6270

E-Mail Hartzema@ufl.edu

EMPLOYMENT

Chief Scientific Officer SureMed Compliance LLC. Birmingham Alabama August 1, 2020-current

Professor and Eminent Scholar Emeritus, Department of Pharmacy Health Care Administration, College of Pharmacy, University of Florida, Gainesville, July 2016 - present.

Scientific Lead, Sentinel Initiative, Immediate Office of the Commissioner, Food and Drug Administration, White Oaks, Maryland, September 1, 2008- August 30, 2009

Professor and Eminent Scholar, Perry A. Foote Chair in Health Outcomes Research and Pharmacoeconomics, Department of Pharmacy Health Care Administration, College of Pharmacy, University of Florida (Gainesville), January 1, 2001 – June 30, 2016.

Affiliate Professor in the Department of Epidemiology and Biostatistics, College of Public Health and Health Professions. University of Florida, January 2, 2007 – June 30, 2016.

Adjunct Professor, Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill, February 1, 2001- Jan 31, 2004

Adjunct Professor, Department of Health Policy and Administration, School of Public Health, University of North Carolina at Chapel Hill, February 1, 2001- January 31, 2004

Professor, Division of Pharmacy Policy and Evaluative Sciences, School of Pharmacy, The University of North Carolina at Chapel Hill (September 1, 1992- December 31, 2000)

Clinical Professor, Department of Epidemiology, School of Public Health, The University of North Carolina at Chapel Hill (March 1, 1997 – December 31, 2000)

Director, Center for Pharmaceutical Outcomes Research, The University of North Carolina at Chapel Hill (September 1, 1994 – December 31, 2000)

Clinical Professor, Department of Health Policy and Administration, School of Public Health, University of North Carolina at Chapel Hill (September 1, 1992 – December 31, 2000)

Associate Professor, Division of Pharmacy Administration, School of Pharmacy, University of North Carolina at Chapel Hill (January 1, 1989 - August 31, 1992)

Clinical Associate Professor, Department of Health Policy and Administration, School of Public Health, University of North Carolina at Chapel Hill (January 1, 1989 - August 31, 1992)

Research Associate, Clinical Epidemiology and Health Services Research, Veterans' Administration Medical Center, Durham, NC (February, 1982 - February, 1984); (October, 1988 – December, 2000)

Research Associate, Cecil G. Sheps Health Services Research Center, University of North Carolina at Chapel Hill (December, 1981 – December, 2000)

Clinical Assistant Professor, Department of Health Policy and Administration, School of Public Health, University of North Carolina at Chapel Hill (January, 1984 - December, 1988)

Assistant Professor, Division of Pharmacy Administration, School of Pharmacy, University of North Carolina at Chapel Hill (June, 1982 - December, 1988)

Instructor, Division of Pharmacy Administration, School of Pharmacy, University of North Carolina at Chapel Hill (July, 1981 - December, 1981)

EDUCATION

University of Minnesota, College of Pharmacy, Department of Social and Administrative Pharmacy, (Ph.D., 1982)

University of Washington, School of Public Health and Community Medicine, Department of Health Services Research, (M.S.P.H., 1978)

University of Utrecht, Medical School, Institute for Hospital Sciences (Graduate Program, 1976)

University of Utrecht, School of Pharmacy (Chemical Pathology, Immunology) (Doctor of Pharmacy, 1977)

University of Utrecht, School of Pharmacy (B.Sc. Pharmacy, 1974)

ACTIVITIES

Editorial Boards:

Medical Care, J.B. Lippincott Company, Philadelphia

Journal of Pharmacoepidemiology, Haworth Press, Inc., April, 1988 - 2008

Drug News and Perspectives, Prous Science, Barcelona, Spain, January, 1988 – present

Expert Review of Pharmacoeconomics and Outcomes Research, 2008- present

The Open Ethics Journal 2007- present

Pulmonary Circulation 2011- present

Column editor: *Pharmacoepidemiology*,

The Annals of Pharmacotherapy, 1987 – 1994

Editorial Advisory Board:

Pharmaceutical Research, 1995 – 1997

International Journal of Pharmacy Practice, 1998-
Mahidol University Journal of Pharmaceutical Sciences 1/1/2005 -
The Open Family Studies Journal Dec 2007-

Boards and Councils:

Advisory Committee of the School of Pharmaceutical Sciences Health Economic Research Institute, Sun Yat-Sen University In Chuangdong, China June 1, 2015 – June 1, 2018.

United States Pharmacopeia, Council of Experts, Nomenclature, Safety and Labeling 2010-2015.

Chair, Data Safety Monitoring Board Effect Of Rasburicase On Acute Kidney Injury, Kidney Function, The Incidence Of Renal Replacement Therapy And All-Cause Mortality Following Cardiac Surgery
8/26/08 (WIRB Action Date); 9/8/2008 (WIRB approval date) - present

Chair, Data Safety Monitoring Board The impact of prophylactic treatment with AP214 on the Proinflammatory Interleukin Response and postoperative Renal Function in patients with coronary artery bypass grafting. 5/23/07 (Charter date) - 8/14/09 (Closure letter date).

Chair, Data Safety Monitoring Board Prophylactic use of Nesiritide (Brain Natriuretic Peptide, BNP) for the prevention of acute renal failure in thoracic aortic aneurysm surgery patients
5/6/2005 (Charter date) – 12/13/07 (Closure letterdate).

International Pharmaceutical Federation (F.I.P.) - Scientific Board, 1988-2001.

Senior Advisor FDA CDRH 2013-current

Manuscript Reviewer: *American Journal of Pharmaceutical Education*
American Journal of Health-System Pharmacy
The Annals of Pharmacotherapy
Chest
Clinical Gerontologist
Clinical Therapeutics
CRC Press, Inc.
The Gerontologist
Health Sciences Consortium
The International Journal of Pharmacy Practice
Journal of the American Pharmaceutical Association
Journal of the Geriatric Society
Journal of Health Services Research
Journal of Pharmaceutical Health Services Research
Journal of Social and Administrative Pharmacy
Minnesota Pharmacist
Oxford University Press
Pharmaceutics
Pharmacoepidemiology and Drug Safety
Social Science and Medicine

Book Reviewer: *Oxford University Press*

Grant Reviewer: *Veterans Administration Health Services Research Program*
Agency for Health Care Policy and Research
Center for Health Promotion Disease Prevention, UNC - Chapel Hill

Faculty seed grants program, UNC School of Pharmacy
HealthCanada
The Netherlands Organisation for Scientific Research (NWO)
National Aeronautic Space Agency
Oncology Grants Program University of Florida
University of Michigan Upjohn Awards
University of Maryland small grants program

Principle Investigator:

Current: NIH/NIDA *A patient self-assessment software combining compliance protocols to improve prescriber confidence, reducibility, and improve patient outcomes. R44DA 051272-01 08/01/2020 – 07/31/2023, total budget 1.6M.*

Co-Principle Investigator:

Observational Medical Outcomes Partnership. Public–Private Partnership FDA-Academe and PhRMA. 2008-2013, total budget \$12M

ADMINISTRATIVE RESPONSIBILITIES

University of Florida COP Faculty Senate 2015-

University of Florida COP Tenure and Promotion Committee 2015-

University of Florida Graduate School Council 2006-2009

University of Florida College of Pharmacy Promotion and Tenure Committee 2006 - 2008

HONORS

Award for Outstanding Contribution to the USP-Standard-setting Process. Jan 2015

Global Advisor, Health Economic Research Institute at Sun Yat-sen University Guangzhou, China 2015-

University of Florida Foundation Research Professorship 2007-2010.

Fellow International Society for Pharmacoepidemiology 2003

PUBLICATIONS

Books:

Ayad A, Hartzema AG. Editors. *Post Authorization Safety Studies*. The PASS Elsevier Press. Published in Japanese December 2022.

Ayad A, Hartzema AG. Editors. *Post Authorization Safety Studies*. The PASS Elsevier Press. July 2018.

Hartzema AG, Tilson HM, Chen AK, editors. *Pharmacoepidemiology and Therapeutic Risk Management*, Harvey Whitney Books, Cincinnati, Ohio, 2008. pp 1004.

Hartzema AG, Porta MS, and Tilson HM, editors. *Pharmacoepidemiology: An Introduction*, Harvey Whitney Books, Cincinnati, Ohio, 1988 - Second Edition, 1991; Third Edition, 1999.

Hartzema AG, Mullins, DC, *Pharmaceutical Chartbook*, The Haworth Press, Binghamton, NY, 1995.

Hartzema AG, *Pharmaceutical Services Chartbook*, Lewis Publishers, Chelsea, Michigan, 1990.

Hartzema AG, et al., editors, *Pharmaceutical Economics (Winst op Recept)*, Kluwer Academic Press, Inc., 1977.

Monographs:

Hartzema AG, Martini N. *Pharmacoepidemiology, The Role of the Clinical Pharmacist*, Upjohn Inc., 1991. (German edition, 1993; Portuguese edition, 1996)

Hartzema AG. *"Outcome Measurements for Pharmacists in the Management of the Chronic Sick Elderly,"* AACP, Washington, DC, 1983.

Publications:

Published-----

Wang S, Meador KJ, Pawasauskas J, Lewkowitz AK, Ward KE, Brothers TN, **Hartzema AG**, Quilliarn B, Wen X. Comparative safety analysis of Opioid agonist treatment in pregnant women with opioid use disorder: a population-based study. *Drug Safety* 46, 257-271, 2023.

Allawan AA, Friedman J, Park H, Segal S, Brumback B, **Hartzema AG**. Comparative safety of sleeve gastrectomy and Roux-en-Y: A Propensity Score Analysis. *World J Surg.* 46(11): 2715-2724, 2022.

Alalwan AA, Friedman J, Alfayez O, **Hartzema AG**. Drug absorption in bariatric surgery patients: A narrative review. *Health Sci Rep* April 26, 2022.

Alawar AA, Friedman J, Park H, Segal R, Brumback BA, **Hartzema AG**. US National Trends in Bariatric Surgery: A Decade of Study. *Surgery* 2021; 170(1): 13-17.

Salas M, Cruz Lopes L, Bernet J, Godman B, Truter I, **Hartzema AG**, Arias A, et al. Challenges Facing Drug Utilization Research in the Latin American region. *Pharmacoepidemiol Drug Saf.* 2020;1–11.

Kim J, **Hartzema AG**. Metabolic syndrome and metabolically healthy status in adults with overweight or obesity, expressing no desire to lose weight. *Obes Res Clin Pract.* 2020 Jan - Feb;14(1):47-53. doi: 10.1016/j.orcp.2019.11.007. Epub 2019 Dec 26.

Kim JH, Tabner A, Johnson G, Brumback B, **Hartzema AG**. Increased risk of acute pancreatitis with codeine use in patients with a history of cholecystectomy. *Digestive Diseases and Sciences.* <https://doi.org/10.1007/s10620-019-05803-3>

Dave C, Goodin AJ, Zhu Y, Wang X, Airwisan, AA, **Hartzema AG**. Prevalence of Maternal Risk Factors related to Neonatal Abstinence Syndrome in a Commercial Claims Database: 2011-2015 Pharmacotherapy <https://doi.org/10.1002/phar.2315>

Chen C, **Hartzema AG**, Xiao H, Wei YJ, Chaudhry N, Ewelukwa O, Glover SC, Zimmermann EM. Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy. *Inflamm Bowel Dis.* 2019 Mar 6. pii: izz001. doi: 10.1093/ibd/izz001. [Epub ahead of print]

Kim J, **Hartzema AG**. Decline in dopamine agonists prescribing and characteristics of drugs prescribed during ambulatory office visits for restless legs syndrome: the National Ambulatory Medical Care Survey 2007-2015. *Sleep Med.* 2019 Feb;54:238-243.

Murimi IB, Ghambaryan A, Decker RD, Lu X; Segal R, Loyo-Berrios NI, Danica Marinc-Dabic D, **Hartzema AG**, Association between Recombinant Human Bone Morphogenetic Proteins and Post-Operative Opioid Use in Lumbar Fusion Procedure Patients: A Propensity-Score Matched Analysis. *World Neurosurg.* 2018 Aug 28. pii: S1878-8750(18)31603-6. doi: 10.1016/j.wneu.2018.07.125. [Epub ahead of print] PMID: 30170146

Dave CV, **Hartzema AG**, Kesselheim AS. Prices of Generic Drugs Associated with Numbers of Manufacturers. *NEJM* (2017) 377; 2: 2597-2598.

Dave CV, Winterstein AG, Park H, Cook RL, **Hartzema AG**. Comparative risk of lipophilic and hydrophilic statins on incident depression: A retrospective cohort study. *J Affect Disord*. 2018 Oct 1;238:542-546.

Kim E, **Hartzema AG**. Adherence and persistence to ropinirole, pramipexole, and gabapentin in patients with newly diagnosed restless legs syndrome *Medicine* (2017), <https://doi.org/10.1016/j.sleep.2017.11.1139>

Dave CV, Kesselheim AS, Fox ER, Qiu P, **Hartzema AG**. High generic drug prices and market competition: A retrospective cohort study. *Ann Intern Med* 2017; 167(3): 145-151.

Alalawan AA, Voils SA, **Hartzema AG**. Trends in the utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation. *Am J Health Syst Pharm*. 2017; 74(16): 1237-1244.

Wen X, **Hartzema A**, Delaney JA, Brumback B, Liu X, Egerman R, Roth J, Segal R, Meador KJ. Combining adverse pregnancy and perinatal outcomes for women exposed to antiepileptic drugs during pregnancy, using a latent trait model. *BMC Pregnancy Childbirth* 2017; 17(1): 10.

Mansoor M, Elgendy IY, Segal R, **Hartzema A**. Reproductive years and the risk of cardiovascular events in women: Insights from the National Health and Nutrition Examination Survey (NHANES). *Journal of Women's Health*.

Hartzema AG. Comments on Prenatal diethylstilbestrol exposure and high-grade squamous cell neoplasia of the lower genital tract. *Am J Obstet Gynecol*. 2016 Sep 26 doi: 10.1016/j.ajog.2016.09.099. [Epub ahead of print]

Wen X, Casey MJ, Rehman S, Santos AH, **Hartzema AG**, Womer KL. Comparison of Utilization and Clinical Outcomes of Belatacept- and Tacrolimus-based immunosuppression in Renal transplant Recipients. *Am J Transplantation (Am J. Transplant*. doi: 10.1111/ajt.13853. 2016)

Chen N, Bussing R, **Hartzema AG**, Shuster J, Segal R, Winterstein AG. Stimulants Use Following the Publicity of Cardiovascular Safety and the Introduction of Patient Medication Guides. *Pharmacoepidemiology and Drug Safety* 2015 DOI: 10.1002/pds.3894.

Xu Y, Zhou X, Suehs BT, **Hartzema AG**, Kahn MG, Moride Y, Sauer B, Liu K, Moll K, Pasquale M, Nair V, Bate A. A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance *Drug Safety* 2015; Jun 9. (Epub ahead of print)

Ayad A, **Hartzema AG** Winterstein AG, Segal R, Lu X, Heneles L. Application of multi-category exposure marginal structural models to investigate the association between long-acting beta-agonists and prescribing of oral corticosteroids for asthma exacerbations in the Clinical Practice Research Datalink. *Value of Health* Jan 20, 2015).

Wen X, Meador KJ, DelaneyJC, Roth J, Segal R, **Hartzema AG**. Utilization of Antiepileptic Drugs in Pregnant Women in Florida Medicaid. *Neurology* 2015 Mar3;84(9): 944-50.

Boyce RD, Ryan PB, Noren GN, Schumie MJ, Reich C, Duke J, Tatonetti NP, Trifiro G, Harpaz R, **Hartzema AG**. Bridging Islands of Information to Establish an Integrated Knowledge base of Drugs and Health Outcomes of Interest. *Drug Safety* 2014;37:557-567.

Stang P, Ryan P, **Hartzema AG**, Madigan D, Overhage JM, Welebob E, Reich CG, Scanecchia T. Development and Evaluation of Infrastructure and Analytic Methods for Systematic Drug Safety Surveillance: Lessons and Resources from the Observational Medical Outcomes Partnership. Chapter in Mann's Pharmacovigilance 3rd edition edited by EB Andrews and N Moore 2013.

Madigan D, Stang, PE, Berlin JA, Schuemie M, Overhage M, Suchard MA, Dumouchel B, **Hartzema AG**, and Ryan PB. A Systematic Statistical Approach to Integrating Information from Observational Studies. *Annu. Rev. Stat. Appl.* 2014. 1:x—x doi:10.1146.

Rivera DR, **Hartzema AG**. Pediatric Exclusivity: Evolving Legislation and Novel Complexities within Pediatric Therapeutic Development. *Ann Pharmacother.* 2014 Mar;48(3):369-79.

Hartzema AG, Chen C. Is fidaxomicin worth the cost? The verdict is still out! *Clin Infect Dis.* 2014 Feb;58(4):604-5. doi: 10.1093/cid/cit774. Epub 2013 Dec 2.

Reply to Simon, Shah et al, and **Hartzema** and Chen. Bartsch SM, Umscheid CA, Fishman N, Lee BY. *Clin Infect Dis.* 2014 Feb;58(4):605-7.

Ryan PB, Schuemie M, Welebob E, Duke J, Valentine S, **Hartzema AG**. Defining a reference set to support methodological research in drug safety. *Drug Safet* 2013; 36: Issue 1 Supplement 33-47.

Hartzema AG, Reich C, Ryan PB, Stang P, Madigan D, Welebob E, Overhage JM. Managing Data Quality for a Drug Safety Surveillance System. 2013; 36 Issue1 Supplement 49-58.

Bird ST, Delaney JA, Brophy JM, Etminan M, Skeldon SC, **Hartzema AG**. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology. *BMJ.* 2013 Nov 5;347

Ryan PB, Stang PE, Overhage JM, Suchard MA, **Hartzema AG**, DuMouchel W, Reich C, Schuemi MJ, Madigan D. A comparison of the empirical performance of methods for a risk identification system. *Drug Safety* 2013; 36: Issue 1 Supplement 15-25.

Stang PE, Ryan PB, Overhage JM, Schuemie MJ, **Hartzema AG**, Welebob E. Variation in choice of study design: Findings from the Epidemiology Design Decision Inventory and Evaluation (EDDIE) Survey. *Drug safety* 2013; 36: Issue 1 Supplement 15-25.

Bird ST, Delaney JAC, Etminan M, Brophy JM, **Hartzema AG**. Drospirenone and non-fatal venous thromboembolism: is there a risk difference by dosage of ethinyl-estradiol? *J Thromb Haemost* 2013; 11: 1059–68.

Bird ST, Etminan M, Brophy JM, **Hartzema AG**, Delaney JA. Risk of acute kidney injury associated with the use of fluoroquinolones. *CMAJ.* 2013 Jun 3. [Epub ahead of print]
PMID: 23734036 [PubMed - as supplied by publisher]

Ryan PB, Madigan D, Stang PE, Marc Overhage J, Racoosin JA, **Hartzema AG**. Response to comment on 'empirical assessment of methods for risk identification in healthcare data'. *Stat Med.* 2013 Mar 15;32(6):1075-7. doi: 10.1002/sim.5725. No abstract available.

Bird ST, Delaney JAC, Etminana M, Brophy JM, **Hartzema AG**. Drospirenone and non-fatal venous thromboembolism: a population based comparative-safety study. (*CMAJ*)

Madigan D, Ryan PB, Schuemie M, Stang PE, Overhage JM, **Hartzema AG**, Suchard MA, Dumouchel W, Berlin JA. Evaluating the Impact of Database Heterogeneity on Observational Study Results. *Am J Epidemiol.* 2013 May 5. [Epub ahead of print]

Bird ST, **Hartzema AG**, Brophy JM, Etminana M, Delaney JAC. Male Breast Cancer and 5-Alpha Reductase Inhibitors, Finasteride and Dutasteride. *Journal of Urology* 2013 May 9. doi:pii: S0022-5347(13)04325-5. 10.1016/j.juro.2013.04.132. [Epub ahead of print]

Bird ST, **Hartzema AG**, Brophy JM, Etminana M, Delaney JAC. Polycystic ovary syndrome; A comparison of clinical practice in the United States and treatment guidelines. *Gynecological Endocrinology Gynecol Endocrinol.* 2013 Apr;29(4):365-9. doi: 10.3109/09513590.2012.743007. Epub 2013 Jan 11.

Dunbar LN, Coleman LJ, Simpson DR, **Hartzema AG.**, Lottenberg R. Transfusion practices in the management of Sick Cell Disease among Florida hematologists/oncologists. 2012, Article 524513, doi: 10.5402/2012/524513.

Bird ST, **Hartzema AG**, Brophy JM, Etminana M, Delaney JSAC. Risk for Venous Thromboembolism in Women with Polycystic Ovary Syndrome; a Population-based Matched Cohort Analysis. *Canadian Medical Association Journal.* 2013 Feb 5;185(2):E115-20. doi: 10.1503/cmaj.120677. Epub 2012 Dec 3.

Ryan PB, Madigan D, Stang PE, Overhage JM, Racoosin JA, **Hartzema AG.** Empirical Assessment of Methods for Risk Identification in Healthcare Data: Results from the Experiments of the Observational Medical Outcomes Partnership. *Stats in Med.* 2012 Sep 27.

Ali AK, **Hartzema AG.** Assessing the Association of Omalizumab use and Arteriothrombotic Events. *J Asthma Allergy.* May 2012; 5:1-9.

Stang PE, Ryan PB, Dusetzina SB, **Hartzema AG**, Reich C, Overhage JM, Racoosin JA. Health Outcomes of Interest in Observational Data: Issues in Identifying Definitions in the Literature. *Health Outcomes Research in Medicine.* | DOI: 10.1016/j.ehrm.2011.11.003 | Published Online: 28 November 2011

Overhage JM, Ryan PB, Reich CG, **Hartzema AG**, Stang PE. Validation of a common data model for active safety surveillance research. *J Am Med Inform Assoc.* 2011 Oct 28. [Epub ahead of print]

Ritho J, Liu H, **Hartzema AG**, Lottenberg R. Hydroxyurea use in patients with sickle cell disease in a Medicaid population. *Am. J.Hematology.* 2011; 86(10): 888-890.

Hartzema AG, Racoosin JA, MaCurdy TE, Gibbs JM, Kelman JA. Utilizing Medicare Claims Data for Real-Time Drug Safety Evaluations: Is it Feasible? *Pharmacoepidemiology and Drug Safety.* 2011; 20: 684-688.

Stang PE, Ryan PB, Racoosin JA, Overhage JM, **Hartzema AG**, Reich C, Welebob E, Scarnecchia T, Woodcock J. Advancing the Science for Active Surveillance: Rationale and Design for the Observational Medical Outcomes Partnership. *Ann Intern Med* 2010; 153: 600-606.

Ryan P, Welebob E, **Hartzema AG**, Stang P, Overhage JM. Surveying Observational U.S. Data Sources and Characteristics for Drug Safety Needs. *Pharmaceutical Medicine* 24(4):231-238, 2010.

Wen X, Meador KJ, DW Loring DW, Eisenschenk S, Segal R, PhD, **Hartzema, AG.** Is Antiepileptic Drug Use Related to Depression and Suicidality Among Patients with Epilepsy? *Epilepsy Behav* 2010 Sep 27, 2010.

Johnson M, Mills TL, Deleon JM, **Hartzema AG**, Haddad J. Lives in isolation: stories and struggles of low-income African American women with panic disorder. *CNS Neurosci Ther.* 2009 Fall;15(3):210-9.

Kauf TL, Coates TD, Huazhi L, Mody-Patel N, **Hartzema AG**. The cost of health care for children and adults with sickle cell disease. *Am J Hematol*. 2009 Jun;84(6):323-7.

LaVista JM, Treise DM, Dunbar LN, Ritho J, **Hartzema AG**, Lottenberg R. Development and evaluation of a patient empowerment video to promote hydroxyurea adoption in sickle cell disease. *J Natl Med Assoc*. 2009 Mar;101(3):251-7.

E Graham SD, **Hartzema AG**, Sketris IS, Winterstein AG. Effect of an academic detailing intervention on the utilization rate of cyclooxygenase-2 inhibitors in the elderly. *Ann Pharmacother*. 2008 Jun;42(6):749-56.

Ilomäki J, Korhonen MJ, Enlund H, **Hartzema AG**, Kauhanen J. Risk drinking behavior among psychotropic drug users in an aging Finnish population: the FinDrink study. *Alcohol*. 2008 Jun;42(4):261-7

Hampp C, **Hartzema AG**, Kauf T. Cost-Utility analysis of rimonabant in the treatment of obesity. *Value Health*. 2008; 11(3):389-99.

Gerhard T, Zineh I, Winterstein AG, **Hartzema AG**. Uncertain Economic Impact of Nesiritide in Advanced Decompensated Heart Failure. *Pharmacotherapy*. 2008;28(1):1e–2e (letter to the editor)

Richardson L, Wang W, **Hartzema AG**, Wagner S. The Role of Health-related Quality of Life in Early Discontinuation of Chemotherapy for Breast Cancer. *The Breast Journal* 2007; 13(6): 581-587.

Johnson MR, **Hartzema AG**, Mills TL, DeLeon JM, Nelson D, Frueh C, Santos A. Ethnic differences in the reliability and validity of a panic disorder screen. *Ethnicity & Health* 2007; 12(3): 1-14.

Hartzema AG, Winterstein AG, Johns T, De Leon J, Baily W, McDonald K, Pannell R. Planning for Pharmacy Health Informaton Technology (pHIT) in Critical Access Hospitals. *American Journal of Health System Pharmacy* 2007 Feb 1;64(3):315-21.

Hartzema AG. The Beginnings of Pharmacoepidemiology in *The Annals*. *Ann Pharmacother* 2006;40:1647-1648.

Hartzema AG, Porta MS, Tilson HH. Introduction to Pharmacoepidemiology. *Ann Pharmacother* 2006;40:1651-1652.

Siege-Riz A-M, **Hartzema AG**, Turnbull C, Thorp J, McDonald T, Cogswell ME. The effects of prophylactic iron given in prenatal supplements on iron status and birth outcomes: A randomized controlled trial. *Am J Obstet Gynecol*. 2006;194(2):512-9.

Winterstein AG, **Hartzema AG**, Johns, TE, De Leon JM, McDonald K, Henshaw Z, Pannell R. Medication Safety Infrastructure in Critical Access Hospitals. *Am J Health Syst Pharm*. 2006 Mar 1;63(5):442-50

Zineh I, Pebanco GD, Aquilante CL, Gerhard T, Beitelhees AL, Beasley BN, **Hartzema AG**. Discordance between availability of pharmacogenomic studies and pharmacogenomic-based prescribing information for the top 200 drugs. *Ann Pharmacother*. 2006; 40(4): 639-44.

Jasti S, Siege-Riz AM, Cogswell ME, **Hartzema AG**. Correction for errors in measuring adherence to prenatal multivitamin/mineral supplement use among low-income women. *J. Nutr*. 2006;136(2):479-83.

Beaver T, Winterstein AG, Ahsan E, Shuster J, Gerhard T, Martin T, Alexander JA, Johnson R, Ejaz A, **Hartzema AG**. Effectiveness of Nesiritide on Dialysis or All-Cause Mortality in Patients Undergoing Cardiothoracic Surgery. *Clinical Cardiology* 2006;29:18-24.

Gerhard T, Zineh I, Winterstein AG, **Hartzema AG**. Pharmacoeconomic Modeling of Nesiritide versus Dobutamine for Decompensated Heart Failure. *Pharmacotherapy* 2006;26(1):34-43.

Richardson L, Tian L, Voti L, **Hartzema AG**, Reis I, Fleming LE, MacKinnon J. The role of teaching hospitals, insurance status and race/ethnicity in the receipt of regional-stage breast cancer in Florida. *AJPH* 2006;96(1):160-6.

Winterstein AG, **Hartzema AG**. The development of quality of care indicators for asthma in community pharmacies. *J of Research in Social & Administrative Pharmacy* 2005; 1: 430-445.

Jasti S, Siega-Riz AM, Coigswell ME, **Hartzema AG**, Bentley ME. Pillcount adherence to prenatal Multivitamin/Mineral supplement use among low income women. *J Nutr.* 2005; 135(5):1093-101.

Zineh I, Gerhard T, Aquilante CL, Beitelhees AL, Beasley BN, **Hartzema AG**. Availability of Pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs. *The Pharmacogenomics Journal* 2004;4(6):354-8.

Hartzema AG. Intranasal vaccine for prevention of influenza in children. *Am J Health-Syst Pharm* 2004; 61: 1716-1720.

Kwon S-Y, **Hartzema AG**, Duncan P, Lai S-M. Disability measures in Stroke: Relationship among the Barthel Index, the Functional Independence Measure, and the Modified Rankin Scale. *Stroke.* 2004; 35: 918-23.

Hendeles L, Hartzema AG. Levalbuterol is not more cost-effective than Albuterol for COPD. Letter to the editor. *Chest.* 2003; 124: 1176.

Shih, Y-CT, **Hartzema AG**, Tolleson-Rinehart S. Labor costs of incontinence care in long-term care. *Urology.* 2003; 62: 442-446.

Kettis Lindblad A, **Hartzema AG**, Jansson L, Feltelius N. Patients' views of priority setting for new medications: a qualitative study of patients with rheumatoid arthritis. *Scandinavian Journal of Rheumatology* 2002; 31: 324-9.

Grabenstein JD, Guess HA, **Hartzema AG**, Koch GG, Konrad TR. Attitudinal factors among adult prescription recipients associated with choice of where to be vaccinated. *Journal of Clinical Epidemiology* 2002; 55: 279-284.

Pradel F, Bush PJ, **Hartzema AG**. Children with asthma use of inhalation devices: techniques, autonomy and perception of ease of use. *Journal for Social and Administrative Pharmacy* 2001; 18; 178-184.

Grabenstein JD, Gues HA, **Hartzema AG**, Koch GG, Konrad TR.¹ Effect of vaccination by community pharmacists among adult prescription recipients. *Medical Care* 2001; 39: 340-8.

Pradel FG, **Hartzema AG**, Bush PJ. Asthma selfmanagement: The perspective of children. *Patient Education and Counseling.* 2001; 45/3:211-24: 1-14.

Grabenstein JD, Guess HA, **Hartzema AG**. People vaccinated by community pharmacists: Descriptive Epidemiology. *J Am Pharm Assoc* 2001; 41:46-52.

Hartzema AG, Day RS, Tolleson-Rinehart S, Sleath B, Bush PJ. Optimizing patient comprehension through medicine information leaflets. Final Report. United States Pharmacopeia, 1999.

Huang X, **Hartzema AG**, Kauf TL, Norwood GJ, Raasch RH. The economic evaluation of antimicrobial therapy for uncomplicated urinary tract infection in women. *Clinical Therapeutics.* 1999; 21:1578-1588.

Pradel FG, **Hartzema AG**, Mutran E, Hanson-Divers C. Physician's over the counter drug prescribing patterns; An analysis of the National Ambulatory Medical Care Survey. *Annals of Pharmacotherapy* 1999; 33:400-5.

Almarsdottir AB, **Hartzema AG**, Bush PJ, Simpson KN, Zimmer C. Childrens' attitudes and beliefs about illness and medicines. A triangulation of open-ended and semi-structured interviews. *J Social Admin Pharmacy* 1997; 14:26-41.

West SL, Savitz SL, Koch G, Sheff KL, Thom BL, Guess HA, **Hartzema AG**. Demographics, health behaviors, and past drug use as predictors of recall accuracy for previous prescription medication use. *Journal of Clinical Epidemiology*. 1997; 50(8):975-80.

Hartzema AG. Foreword to Standards for Economic Evaluation of Drugs. *Medical Care*, 1996; 125:1-2.

Sirpa W, Kirsti V, Korhonen M, **Hartzema AG**, Euland H. Self-initiated modification of hypertension treatment in response to perceived problems. *Annals of Pharmacotherapy* 1995; 29:1213-7.

West SL, Savitz DA, Koch G, Strom BL, Guess H, **Hartzema AG**. Recall accuracy for prescription medications: self-report compared with database information. *Am J Epidemiol* 1995; 142:1103-12.

Hanson EC, **Hartzema AG**. Evaluating pictograms as an aid for counseling elderly and low-literate patients. *Journal of Pharmaceutical Marketing and Management* 1995; 9(3):41-54

Hartzema AG. Implications for health policy: Chapter in Viewpoints Section. J.P. Bush, Editor, *Children, Medicines and Culture*, The Haworth Press, Binghamton, N.Y., 1995.

Hartzema AG. Teaching therapeutic reasoning through the case-study approach: Adding the probabilistic dimension. *American Journal of Pharmaceutical Education*. 1994; 58:436-440.

Hartzema AG. The patient consultation mandate: unresolved issues and viewpoints. Implications for management education and experimental training. *American Journal of Pharmacy Education* 1993; 57:433-436.

McLeod DC, Cohn, WG, Thayer CF, Perfetto EM, **Hartzema, AG**. Pharmacoepidemiology of Bleeding Events After Use of 4-Alteplase or Streptokinase in Acute Myocardial Infarction. *DICP The Annals of Pharmacotherapy*. 1993; 27:956-62.

Boyd AF, **Hartzema, AG**. Computerized monitoring protocols as a pharmaceutical care practice enhancement: a conceptual illustration using diabetes mellitus, *DICP The Annals of Pharmacotherapy*. 1993; 27:963-6.

Grabenstein JD, **Hartzema AG**, Guess HA, Johnston WP. Community Pharmacists as Immunisation Advocates: a pharmacoepidemiologic experiment. *International Journal of Pharmacy Practice*. 1993; 2:5-10.

Sloane PD, Baldwin R, Montgomery R, Hargett F, **Hartzema AG**. Left-Sided Leg Edema of the Elderly: A Common Variant of the Iliac Compression Syndrome. *Journal American Boards of Family Practice* 1993; 6:1-4.

Grabenstein JP, **Hartzema AG**, Guess HA, Johnston WP, Rittenhouse BE. Community Pharmacists as Immunization Advocates: Cost-Effectiveness of a Cue to Influenza Vaccination. *Medical Care*, 1992; 30: 503-513.

Hartzema AG. Commentary: Pharmacoepidemiology. Its relevance to clinical practice. *Journal of Clinical Pharmacy and Therapeutics*, 1992; 17:73-74.

Grabenstein JD, Schroeder, DC, Bjornson DC, **Hartzema AG**. Pharmacoepidemiology and Military Medical Automation: Opportunity for Excellence. *Military Medicine*, 1992. 157;6: 302-307.

Hartzema AG, Perfetto EM, Baldwin R, Johnson C. Strengthening the drug management cycle in a sample of North Carolina Resthomes. Final report to the John A. Hartford Foundation Center for Health Promotion and Disease Prevention, University of North Carolina at Chapel Hill, December 1992.

Hartzema AG. Quality of Life Assessments in Clinical Trials, Editor B. Spilker. Book Review. *International Pharmacy Journal* 1992;6:19.

Hartzema AG. Guidelines for Evaluating the Pharmacoepidemiologic Literature. *The Annals of Pharmacotherapy* 1992;26: 96-98.

Hartzema AG. Improving the Quality of Pharmaceutical Care in Board and Care Facilities. *Clinical Outcomes* 1991;2:10-12.

Hartzema AG, Perfetto EM. Internal Rate of Return and Pharmaceutical Sciences Manpower Supply. *Pharmaceutical Research*, 1991;8:676-682.

Porta MS, **Hartzema AG**. The Contribution of Epidemiology to the Study of Drugs. (Translated in Japanese and distributed by the Japanese Pharmaceutical Manufacturers Association to membership firms.)

Hartzema AG, Baldwin R, Perfetto EM, Johnson C. Reducing medication administration errors in family care homes through a program of on-site education and technical assistance. Final report to the Kate B. Reynolds Health Care Trust. Center of Health Promotion and Disease Prevention, University of North Carolina at Chapel Hill, May 1991.

Hartzema AG. Control and Validity in Research Design. In: Nnadi-Okolo E., ed. *Health Research and Methodology*. Boca Raton, FL: CRC Press;1990.

Hartzema AG, Temple D, Wertheimer AI. The organization of continuing education, Part II. Results of an international survey, *Pharmacy International*, 1990; 4:96-101.

Hartzema AG, Temple D, Wertheimer, AI. The organization of continuing education, Part I. An international literature review, *Pharmacy International* 1990;4:56-59.

Hartzema AG, Godbout N, Lee SD, Konrad TR. Measuring Health Locus of Control Among Caregivers in Charge of Medication Administration in Long Term Care Settings. *Journal of Social and Administrative Pharmacy*, 7(2):84-92, 1990.

Porta MS, Ruiz XM, **Hartzema AG**. Pharmacoepidemiology: the name is new; what else is new?, *Drug News and Perspectives*, 1:243-245, 1988.

Hartzema AG, Blom L. Clinical education for hospital pharmacists in the Netherlands and the United States of America: some observations, *Pharmaceutisch Weekblad Scientific Edition*, 10:158-169, 1988.

Hartzema AG. Comment: Importance of Pharmacoepidemiology. Author's reply. *Drug Intelligence and Clinical Pharmacy*, 22(5):429-430, 1988.

Hartzema AG, Rosenberg L, Temple DJ, Wertheimer AI. Drug information management and provision skills taught to pharmacy students: an international perspective, *Journal of Social and Administrative Pharmacy*, 5, 59-63, 1988.

Hartzema AG, Phillips J. Mail order pharmacy: a real or perceived threat to the economic future of retail pharmacy, *The Carolina Journal of Pharmacy*, 67, 7-14, 1987; *Palmetto Pharmacist*, 27:12-15, 1988; *The Journal of Kansas Pharmacy*, 62:6-9, 25, 1988.

Greenspan DB, **Hartzema AG**, Darrel Estes W. Implementation of a total parenteral nutrition program in the skilled nursing facility: role of the nursing director, *Nursing Homes*, 36, 24-26, 1987.

Hartzema AG. Evolving health care systems; academic implications for content and skill, *American Journal of Pharmaceutical Education*, 51, 399-401, 1987.

Serradell J, Bjornson DC, **Hartzema AG**. Drug utilization study methodologies: national and international perspectives, *Drug Intelligence and Clinical Pharmacy*, 21, 994-1001, 1987.

Hartzema AG, Porta MS, Tilson HM, Introduction to the Pharmacoepidemiology Series, *Drug Intelligence and Clinical Pharmacy*, 21, 739-741, 1987.

Porta MS, **Hartzema AG**. Pharmacoepidemiology: the contribution of epidemiology to the study of drugs, *Drug Intelligence and Clinical Pharmacy*, 21, 741-746, 1987.

Hartzema AG, Blom L. Quality of clinical education, *Ziekenhuis Farmacie*, 3, 104-105, 1987, Suppl 1.

Hartzema AG, Konrad TR. Prevention of drug problems in domiciliary care facilities, (Position Paper), *The Nation's Health*, 17, 21-22, 1987.

Hartzema AG, *Organization of Health Care Delivery: Social Forces*, Wertheimer AI, Smith MC ed., A Casebook in Social and Behavioral Pharmacy, Harvey Whitney Books, Cincinnati, Ohio, 1987.

Hartzema AG. Capitation reimbursement for pharmacy services, Proceedings from the Sixth International Conference on Pharmacy Economics, PPSI, 1986.

Gagnon JP, **Hartzema AG**, Mackowiak JI, Diamond WD. Identifying class problems in Schools of Pharmacy, *American Journal of Pharmaceutical Education*, 49, 246-250 (1985).

Hartzema AG. Report on the competencies in social and behavioral sciences. Submitted to the Pharmacy Administration Section of the American Association of Colleges of Pharmacy, Summer 1985.

Hartzema AG and Thomas III J. The basics of bar code technology in inventory control. *Current Concepts in Retail Pharmacy Management*, 3, 7-13 (1985).

Hartzema AG. Psycho-social factors in self-medication. In: LE Fryklof and R. Westerling, eds. *Self-Medication*. Swedish Pharmaceutical Press, Stockholm, 1984.

Hartzema AG and Wertheimer AI. Comparison of three populations on their "expectancies" from self-medication vs. medical care. *Journal of Social and Administrative Pharmacy*, 1, 80-86 (1983).

Hartzema AG, Christensen DB, and Logerfo J. Non-medical factors associated with the prescribing volume among family practitioners in an HMO. *Medical Care*, 21, 990-1000 (1983).

Hartzema AG, Pancorbo S, and Davis S. Personality traits and theophylline metabolism. *Biopharmaceutics and Drug Disposition*, 3, 311-316 (1982).

Hartzema AG. Software for Apple II and Haynes Micro-communication software for Apple II and Haynes micro-modem with UNC and TUC Computer Centers. October, 1982.

Hartzema AG. History of pharmaceutical sciences. Teaching the History and Sociology of Pharmaceutical Sciences, 7, 4, September, 1982.

Hartzema AG. Self-medication: In the scheme of things. *Pharmacy Internationale*, 3, 57-59 (1982).

Hartzema AG. Drugs and the aged, by WD Poe and DA Holloway. In: *Journal of the American Geriatrics Society*, 30, 156 (1982).

Hartzema AG, Wertheimer AI, and Rudelius W. Discriminating high and low prescribers. *Journal of Health Care Marketing*, 1, 8-17 (1981).

Hartzema AG. Pharmacy Practice: social behavioral aspects, 2nd ed., edited by AI Wertheimer and MC Smith. In: *Pharmacy Internationale*, 3, XI (1981).

Christensen DB, Campbell WH, Madsen S, **Hartzema AG**, and Nudelman PM. Documenting outpatient problem intervention strategies in an HMO. *Medical Care*, 19, 104-117 (1981).

Hartzema AG. Domme patient of domme apotheker. *Folia Pharmaceutica*, 63, 240-243 (1976).

Hartzema AG. Het fenomeen goodwill. *Folia Pharmaceutica*, 63, 186-188 (1976).

¹ Pharmacy Practice Research Award December 2002, American Society for Health-system Pharmacists, J. Grabenstein, H. Guess, AG Hartzema

TECHNICAL REPORTS

Winterstein AG, Taylor MD, **Hartzema AG**, Segal R. The economic impact of glycemic control as measured by glycosylated hemoglobine: a systematic review of diabetes outcomes studies. Agency for Health Care Administration, March 2004.

PRESENTATIONS AND ABSTRACTS (Invited and Contributed)

Hartzema AG. Pharmacoepidemiological methods. The eight affiliated hospital. Sun Yat-Sen University. Nov 3, 2018, Shenzhen China.

Hartzema AG. Validation of Safety Signals: the good and the bad. 11 th Asian Conference on Pharmacoepidemiology. October 28 2018, Xian, China.

Hartzema AG. Seminar in Pharmacoepidemiology and Pharmacoeconomics. University Pancasila, Aston Priority Hotel, July 26 2018, Jakarta Indonesia.

Hartzema AG . Patient preferenceces for Better quality of life. Indonesia Chapter Conference 2018. Yogyakarta, July 21-24, 2018.

Chen, C., Ewelukwa, O., Zimmermann, E. M., **Hartzema AG**, Glover, S. C., Eldar-Lissai, A. The risk of serious infections in patients with inflammatory bowel disease treated with mono- and combination therapy. Digestive Disease Week, Monumental Developments in Science & Medicine, poster session Washington DC, June 2, 2018.

Chen, C., Ewelukwa, O., Zimmermann, E. M., **Hartzema AG**, Glover, S. C., Eldar-Lissai, A. Comparative Persistence of Biologics in the Treatment of Inflammatory Bowel Disease: A Truven Marketscan Database Study. *Gastroenterology*, 2017:152(5), S594.

Hartzema AG. Pay for Outcome Performance: The role of pharmacoepidemiology Yoggyakarta, Indonesia 24/7/2018

Hartzema AG. Strengthening the clinical evidence provided by observational studies. Pharmacoepidemiology and Clinical Research. Kuala Lumpur, Malaysia Oct 2, 2017.

Hartzema AG. New insights in pharmacoepidemiology. Conference de Pharma and Techno Vigilance. October 14, 2016. Merida, Yucatan Mexico.

Albogami Y, **Hartzema AG.** Asthma hospitalization differences between generics and brand of Montelukast. ICPE meeting Dublin Ireland. August 28, 2016. Poster presentation.

Albogami Y, **Hartzema AG.** Trends in asthma medications use in the United States from 2008-2014. ICPE meeting Dublin Ireland. August 28, 2016. Poster presentation.

Wen X, Womer KL, Casey MJ, Santos AH. **Hartzema AG.** Utilization of Belatacept in renal transplant recipients in USA. ICPE meeting Dublin Ireland. August 28, 2016. Poster presentation.

Dave C, **Hartzema AG,** Park H, Winterstein AG. Baseline and Time-varying Determinants of statin Adherence. ICPE meeting Dublin Ireland. August 27, 2016. Oral presentation

Chen C. **Hartzema AG.** Trends in the utilization of biologics for inflammatory bowel disease in the United States. ICPE meeting Dublin Ireland. August 27, 2016. Oral presentation.

Dave C, **Hartzema AG,** Winterstein AG. Performance of Machine Learning Algorithms in Statistical modelling of 30 day heart failure readmission risks using automated and investigator specified co-variables. ICPE meeting Dublin Ireland. August 26, 2016. Poster session.

Hartzema AG. American Laws and Regulations related to Food and Drugs. Drug safety and modern vocational education expert lectures. Shandong Medical Technician College. June 22, 2016 Shandong China. Invited.

Dave C, **Hartzema AG,** Park H, Winterstein AG. Baseline and Time-Varying Determinants of Statin Adherence. 32nd International Conference of Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland; August 25-28, 2016. Pharmacoepi Drug Saf 2016;25(Suppl. 3):274

Alalwan A, Voils S, **Hartzema AG.** Trends in the Utilization of Warfarin and Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation. ISPOR Poster presentation 5/24/2016 Washington DC, abstract in Value in Health 19 (216) A 42. (Poster award selection).

Mansoor H, Segal R, Hartzema A. Reproductive years and the risk of cardiovascular events in women: Insights from the National Health and Nutrition Examination Survey (NHANES). American Heart Association Annual Scientific Sessions. November 2015. Orlando, FL.

Zhou X, Yihua X, Suehs BT, **Hartzema AG,** Kahn MG, Moride Y, Sauer B, Liu Q, Moll K, Pasquale M, Nair V, Bate A. Observational Medical Outcomes Partnership (OMOP) and Mini-Sentinel (MS) Common Data Models and Analytics: A systematic data driven comparison. ISPE Boston August 25, 2015.

Dave C, He J, Winterstein AG, **Hartzema AG.** The incidence of solid tumors in a healthcare database compared to SEER. ISPE Boston August 25, 2015.

Chen C, Bautista RE, **Hartzema AG.** Utilization and adherence pattern of generic and brand-name drugs in the treatment of epilepsy. ISPE Boston August 26, 2015

Kim JH, Alrwisan A, Park H, **Hartzema AG.** Restless legs syndrome: epidemiology and treatment. ISPE Boston, August 26, 2015.

Hartzema AG, Salas M. Oral session moderators Who knows what about risk.

Dave C, **Hartzema AG**. Trends in healthcare utilization and cost of epilepsy across ages 0-90. ISPE Boston August 25, 2015

Dave C, **Hartzema AG**, Andrade E, Winterstein AG. Drug utilization of childhood epilepsy. ISPE Boston August 25, 2015.

Allawan AA, Xu X, **Hartzema AG**. Influenza vaccine utilization: a comparison between urban and rural counties in Florida. ICPE Boston 2015

Allawan, AA, Voils SA, **Hartzema AG**. Trends in the Utilization of Warfarin and the New Oral Anticoagulants in Atrial Fibrillation Patients. ISPE Boston August 24, 2015

Dave C, **Hartzema AG**. Costs of generic medications, and its association with industry consolidation. ISPE Boston August 24, 2015

Brobert G, **Hartzema AG**. Co-Chairs. Gain on Pain session. 30th ICPE, Taipei, Oct 27, 2014

Chen C, Eworuke E, Schelfhout J, **Hartzema AG**. Hospital Volume and Outcomes for Total Hip Arthroplasty. 30th ICPE, Taipei, Oct 27, 2014

Schelfhout J, Chen C, **Hartzema AG**. Use of Optional ICD-9-CM Articulating Surface Codes for Total Hip Arthroplasty in US Claims Data. 30th ICPE, Taipei, Oct 27, 2014

Wen X, Meador KJ, Delaney JC, Liu X, Roth J, Segal R, Egerman R, **Hartzema AG**. Combining Adverse Perinatal and Pregnancy Outcomes Using a Latent Trait Model. 30th ICPE, Taipei, Oct 26, 2014

Ryan P, Schuemie M, Madigan D, Suchard M, Stang P, Overhage JM, Reich C, Khayer M, **Hartzema AG**, DuMouchel B, Berlin J. Health Outcomes and Medical Effectiveness Research (HOMER): A Systematic Approach to Exploring Hill's Causal Viewpoints in Observational Data. 30th ICPE, Taipei, Oct 25, 2014

Hartzema AG. Active drug safety surveillance; Are we there? (Invitational presentation) Gordon Research Conference, Boston June 5, 2014

Hartzema AG. Big Data. ISPOR presentation Montreal June 2, 2014. (Invitational presentation).

Ali AK, Winterstein A, Hendeles L, Lu X, Segal R, **Hartzema A**. Comparison of rates of prescribing oral corticosteroids for asthma exacerbations between step-down therapy approaches among initiators of inhaled corticosteroids and long-acting beta-agonist combination therapy. Journal of Allergy and Clinical Immunology. February 2014; 133(2S):AB177 [Abstract No. 611].

Hartzema AG. Pharmacoepidemiology and Datamining. Second Ibero-American Symposium on Social Pharmacy: Ecopharmacovigilance. Universidad Autonoma Metropolitana Mexico City. September 26, 2013

Hartzema AG. Reliability of racial and ethnic classification in large data sources and its contribution to data heterogeneity (D3). FIP Social and Administrative Pharmacy Section. Dublin Sept 4, 2013

Hartzema AG. Chair: Brain, Skin and Bones Session. 29th International Conference on Pharmacoepidemiology and Therapeutic Risk management. Montreal, Canada August 27, 2013.

Riviera D. **Hartzema AG**. Pediatric Exclusivity: Evolving Legislation and Novel Complexities with Pediatric Therapeutic development. Poster Session B: SIG Pediatrics. 29th International Conference on Pharmacoepidemiology and Therapeutic Risk management. Montreal, Canada August 27, 2013.

Bird ST, Etminana M, Brophy JM, Delaney JAC, **Hartzema AG**. Drospirone and risk for venous thromboembolism; a comparison by dosage of ethinyl-estradiol. SIG Database. 29th International Conference on Pharmacoepidemiology and Therapeutic Risk management. Montreal, Canada August 27, 2013.

Bird ST, Etminan M, Brophy JM, **Hartzema AG**, DeLaney JAC. Fluorquinolones and risk for acute kidney injury. SIG Database. 29th International Conference on Pharmacoepidemiology and Therapeutic Risk management. Montreal, Canada August 27, 2013.

Schelfhout J, Dabic-Marinac D, Loyo-Berrios N, Ghambarvan A, **Hartzema AG**. A Total Hip Arthroplasty Utilization and Safety. FDA fellow presentation Rockville, Md August 2013

Rivera DR, Hartzema AG. Pediatric Exclusivity: Evolution of Legislation that addresses the complexities of pediatric therapy development. ISPE Montreal Augst 25, 2013

Ali AK, **Hartzema AG**, Hendeles L, Lu X, Winterstein AG, Segal R. Long-acting beta-agonists and asthma exacerbations requiring short courses of oral corticosteroids: a multi-category exposure marginal structural models analysis. Value in Health. May 2013; 16(3):A231 [Abstract No. PRS2].

Ali AK, **Hartzema AG**. Prescribing long-acting beta-agonists as monotherapy to adults with controlled and uncontrolled asthma. Value in Health. May 2013; 16(3):A241 [Abstract No. PRS54].

Etminan M, Brophy J, **Hartzema AG**, Delaney J, Bird S. 5-alpha reductase inhibitors and risk of male breast cancer. American Society of Clinical Oncolog. May 30-June 4. Chicago, Il.

Hartzema AG. Moderator. Keeping your Eyes open. ISPE Symposium Barcelona August 26, 2012

Wen X, Meador KJ, Winterstein AG, **Hartzema AG**. Utilization of antiepileptic drugs in Florida Medicaid women with epilepsy of childbearing age. Pharmacoepidemiology and drug safety 2012; 21: (Suppl. 3): 322. Abstract 693.

Hartzema AG. Active Drug Safety Surveillance and how it contributes to Pharmacy's Knowledge Base. Keynote address. The 1ste Technosphere 2012 Conference, the 14th Annual SACPAW Congress and the 2nd International Conference of AUST College of Pharmacy and Health Sciences. AUST, Ajman, UAE. Feb 7, 2012.

Guo JD, Shuster JJ, **Hartzema AG**. Random-Effects Approaches Comparisons in Meta-Analysis: Data Simulation with Binomial Outcomes. . The 6th Asian Conference on Pharmacoepidemiology (ACPE) and 2011 Annula meeting of the Committee of Pharmacoepidemiology of Chinese Pharmaceutical Association (AMCP-CPA). Beijing China October 29, 2011

Ali AK, **Hartzema AG**, Hendeles L, Lu X, Winterstein AG, Segal R. Long-Acting Beta-Agonists and Asthma Exacerbations Requiring Short Courses of Oral Corticosteroids: A Multi-Category Exposure Marginal Structural Models Analysis. Value in Health. May 2013;16(3):In Press [Abstract No. PRS2].

Ali AK, **Hartzema AG**. Prescribing Long-Acting Beta-Agonists as Monotherapy to Adults with Controlled and Uncontrolled Asthma. Value in Health. May 2013;16(3):In Press [Abstract No. PRS54].

HartzemaAG. Active medical product safety surveillance system: the Sentinel Initiative. 1st International Conference July 20-21, 2011 Patient Safety from product to patient care and translational research. Ubon Ratchathani, Thailand.

Hartzema AG. Symposium Chair and Speaker. Pharmacovigilance: Active Surveillance. The observational Medical Outcomes Partnership Experience. International Congress of Pharmacology, Mexico May 19 2011.

Hartzema AG. Datasources in Pharmacoepidemiology for exposure, endpoints and covariates. International Congress of Pharmacology, Mexico May 19 2011.

Hartzema AG, Ryan PB, Stang PE, Racoosin JA, Overhage JM, Madigan D. Observational Medical Outcomes Partnership: Review of Methodological Research for Active Drug Safety Surveillance. The 16th Annual meeting of Japanese Society for Pharmacoepidemiology and the 5th Asian Conference on Pharmacoepidemiology (joint meeting). Oct 31, 2010, Tokyo, Japan (poster)

Hartzema AG. FDA's Sentinel Initiative? A National Strategy for monitoring Medical Product safety. The 16th Annual meeting of Japanese Society for Pharmacoepidemiology and the 5th Asian Conference on Pharmacoepidemiology (joint meeting). Oct 30, 2010, Tokyo, Japan (main symposium)

Hartzema AG (Chair), Ryan P, Nair V. Developing tools for conducting observational database research across a network of realworld data sources. ISPOR 15th Annual International Meeting. Atlanta May 18, 2010.

Overhage J, Mandl K, Brown J, Pezalla E, **Hartzema AG** (Chair). Informatics opportunities and Challenges for Improving Drug Safety. AMIA. San Francisco. Nov 17, 2009.

Ritho JN, Mayhew DY, **Hartzema AG**, Huazhi L, Lottenberg R. Hydroxyurea use in Sickle Cell Disease patients in a Florida Medicaid population. American Society of Hematology, Dec 9, 2007, Atlanta GA. (podium presentation)

Hartzema AG, Kauf TL, Coates TD, Huazhi L, Mody-Patel N. Economic Burden of Sickle Cell Disease among Children and Adults. American Society of Hematology, Dec 8, 2007, Atlanta GA. (poster)

Nash R, Odedina F, Campbell E, Xiao H, **Hartzema B**, Larose-Pierre M, Corey-Lisle, P. The economic burden of prostate cancer: a comparison of African American and Causcasian men. AACR Conference on the Science of cancer Health Disparities. November 28, 2007, Atlanta, GA. (poster)

Gerhard T, Winterstein AG, Shuster, JJ, Johnson, JA, **Hartzema AG**, Pepine CJ. Estimating Effects of Antihypertensive Therapy on Adverse Outcomes in the Presence of Time-Dependent Confounding by Blood Pressure. Pharmacoepidemiology and Drug Safety, 2007; 16:S32 (podium presentation).

Gerhard T, Winterstein AG, Shuster, JJ, Johnson, JA, **Hartzema AG**, Pepine CJ. Impact of Operationalization of Longitudinal Blood Pressure on Adverse Outcomes. Pharmacoepidemiology and Drug Safety, 2007; 16:S115 (poster).

Gerhard T, Winterstein AG, Shuster, JJ, Johnson, JA, **Hartzema AG**, Pepine CJ. Use of Average Surrogate Values Introduces Bias: A Simple Simulation. Pharmacoepidemiology and Drug Safety, 2007; 16:S115-116 (poster).

Hartzema AG. The development of a cost model for complications in diabetes II patients. Duphat 2007. Dubai International Pharmaceuticals & Technologies Conference & Exhibition. Dubai 2007 March 21, 2007. (invited)

Hartzema AG. Pharmacoeconomics of Hepatitis B. Congress on the political and economic aspect of Hepatitis B. Hacettepe University. Ankara. Dec 16, 2006. (invited)

Levette Dunbar L, Coleman L, **Hartzema AG**, De Leon J, Lottenberg R. Transfusion Practices in the Management of Sickle Cell Disease among Florida Physicians.

Graham SD, **Hartzema AG**, Sketris I, Winterstein A. Effect of academic detailing on COX-2 utilisation rates in the Nova Scotia seniors population. Joint CAHSR / PHC-CHSRF Symposium, Sept 19, 2006. Vancouver, British Columbia.

Dunbar LN, LaVista JM, Ritho J, De Leon JM, **Hartzema AG**, Treise DM, Lottenberg R, Evaluation of an educational video to enhance the use of hydroxyurea.

Hartzema AG. Secondary signal detection in pharmacovigilance. Congreso Panamericano de Farmacia. Mexico City, November 16, 2006 (invited)

Graham S, **Hartzema AG**, Sketris I, Winterstein AG. Effect of academic detailing on COX-2 utilisation rate in the Nova Scotia seniors population. CHSRF Primary healthcare network symposium. Vancouver, Sept 19, 2006.

Hartzema AG. Drug Utilization Research, Department of Preventive Medicine, University of Alabama Birmingham, July 6, 2006.

Hartzema AG. Datamining techniques and secondary signal detection. School of Public Health, University of Alabama, July 5, 2006.

Hartzema AG, Winterstein AG, Snedecor S, Taylor M, Segal R, Frank R. A Diabetes II cost model to project savings accruing from disease management programs. 8th International Symposium on Pharmaceutical Sciences. June 16, 2006, Ankara, Turkey.

Hartzema AG. Establishing a framework for Health Outcomes research. Fudan University Shanghai China. March 6, 2006. Invited lecture

Hartzema AG. Gehe Forum Futurum 2005. Health Information Technology: Wie Daten und Software zur pharmazeutischen Kernkompetenz werden. November 10, 2005, Miami.

Hartzema AG. The Origins of health outcomes research and its implications for public health. Graduate student council, ISPOR European Conference, November 7, 2005, Florence Italy. (invited)

Gerhard T, Winterstein AG, Shuster J, **Hartzema AG**. Workshop on propensity scores. ISPOR European conference, November 6, 2005 Florence.

Hartzema AG, Winterstein AG, Segal R, Snedecor S, Taylor MD. The economic evaluation of Diabetes II disease management programmes. World Congress of Pharmacy and Pharmaceutical Sciences September 4, 2005 Cairo.

Gerhard T, Winterstein AG, Shuster JJ, **Hartzema AG**. Propensity-Score-Based analysis compared to multivariate logistic regression: implications for clinical utility. 21st International Conference on Pharmacoepidemiology and Risk Management. Nashville, August 21-24, 2005. Pharmacoepidemiology and Drug Safety 2005;14(suppl 2): S59-S60 (oral presentation).

Winterstein AG, Beaver TM, Shuster JJ, Gerhard T, Alexander AA, **Hartzema AG**. Effectiveness of nesiritide on risk for dialysis or death after adult open heart surgery. 21st International Conference on Pharmacoepidemiology and Risk Management. Nashville, August 21-24, 2005. Pharmacoepidemiology and Drug Safety 2005;14(suppl 2): S65-S66 (oral presentation).

Hartzema AG, Winterstein AG, DeLeon J, Johns T, Widmer A, Chamberlain J, Bailey W, Winkler R, Pannell R, Henshaw Z, McDonald K. Health information technology for medication safety in critical Access Hospitals. 2005 Patient safety and National resources Center Annual Conference, Washington DC, June 8 2005.

Hartzema AG. Economic model for the evaluation of Diabetes II disease management programs. Dalhousie University, Canada, June 2, 2005. (invited).

Taylor MD, Winterstein AG, **Hartzema AG**, Segal R, Frank RG, MacLean R. The impact of glycemic control on the incidence of diabetic complications. Tenth Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. May 15-18, 2005 Washington, DC. Value in Health 2005; 8(3):256 (oral presentation).

⁴Snedecor SJ, **Hartzema AG**, Schiller C. Cost-effectiveness of HIV treatment innovations of greater efficacy than highly active antiretroviral therapy (HAART). Tenth Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. May 17, 2005 Washington, DC

Zineh I, Pebanco GD, Aquilante CL, Gerhard T, Beitelhees AL, Beasley BN, **Hartzema AG**. Discordance between availability of pharmacogenomic studies and pharmacogenomic-based prescribing information for the top 200 drugs (Submitted as poster ACCP).

Hartzema AG, Chair and Presenter Symposium Achieving Medication Safety in Small Rural Hospitals. ASHP Midyear, Orlando, December 8, 2004.

Hartzema AG. Health Information Technology in Critical Access Hospitals. Florida Rural Health Summit. Altamonte Florida, December 7, 2004.

Jasti S, Siega-Riz AM, **Hartzema AG**, Cogswell ME. Adjustment For Measurement Error In Adherence To Prenatal Multivitamin/Mineral Supplements. Experimental Biology April 2005 (Submitted).

Richardson LC, Wang W, **Hartzema AG**. Early treatment discontinuation: role of health related quality of life (Hr-QL). Departments of Medicine and Pharmacy, University of Florida, Gainesville, FL, Department of Biostatistics, Harvard University, Boston, Massachusetts. Abstract # 3073. 27th Annual San Antonio Breast Cancer Symposium, December 9, 2004

Hartzema AG. First Plenary Presentation. Applying patient outcomes and pharmacoeconomics in patient care. Second Biennial Conference: Health Sciences Research and Education in Focus in the Caribbean. Port of Spain, Trinidad. October 12, 2004.

Hartzema AG. Workshop: Introduction to Pharmacoeconomics. Second Biennial Conference: Health Sciences Research and Education in Focus in the Caribbean. Port of Spain, Trinidad. October 11, 2004.

Kwon S, Duncan P, **Hartzema AG**, Lai S-M. Utility in patients with stroke related disability. ISPE, 20th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Bordeaux France, August 21 - 25, 2004

Zineh I, Gerhard T, Aquilante CL, Beitelhees AL, Beasley BN, **Hartzema AG**. Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs. Pharmacotherapy 2004;24(10):1459.

Zineh I, Gerhard T, Aquilante CL, Beitelhees AL, Beasley BN, **Hartzema AG**. Availability of Pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs. Podium presentation ACCP Annual meeting, Dallas, 10/25/2004

Gerhard T, Zineh I, **Hartzema AG**. Cost-effectiveness of Nesiritide versus Dobutamine in patients with acutely decompensated heart failure. ISPE Bordeaux, 8/24/2004

Kanjanarat P, **Hartzema AG**. Cost-effectiveness of Aspirin for acute ischaemic stroke in patients with Atrial Fibrillation. ISPE Bordeaux, 8/24/2004

Zineh I, Gerhard T, Aquilante CL, Beitelhees AL, Beasley BN, **Hartzema AG**. Availability of Pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs. Poster ISPE Bordeaux, 8/23/2004

Richardson LC, Wang W, **Hartzema AG**. Early treatment discontinuation: role of health related quality of life (Hr-QL). Departments of Medicine and Pharmacy, University of Florida, Gainesville, FL, Department of Biostatistics, Harvard University, Boston, Massachusetts. Robert Wood Johnson Clinical Scholars program (Accepted).

Richardson L, **Hartzema AG**, Voti L, MacKinnon J, Fleming L, Trapido E. Chemotherapy for regional stage breast cancer in Florida. *Proc Am Soc Clin Oncol*. 2003; 22: 55. (abstr 2154).

Snedecor SJ, Schiller KC, **Hartzema AG**. Lifetime costs associated with HIV-infected patients' clinical characteristics. Southern Pharmacy Administration Conference, Ft Lauderdale June 12, 2004

Schiller KC, **Hartzema AG**. An economic analysis of calcium channel blockers for acute traumatic brain injury. ISPOR 9th Annual International Meeting, Crystal City, May 17, 2004.³

Mehta SR, Mayhew DY, DeLeon JM, **Hartzema AG**, Lottenberg R. The health-related quality of life experiences of young adults with sickle cell disease: a qualitative assessment. ISPOR 9th Annual International Meeting, Crystal City, May 18, 2004.

Graham SD, **Hartzema AG**. The development of propensity scores from administrative databases: for the analysis of the effectiveness of an osteoarthritis academic detailing service on prescribing behaviour. ISPOR 9th Annual International Meeting, Crystal City, May 17, 2004.

Kwon S, **Hartzema AG**, Duncan P, Lai S. Disability in stroke outcomes research. American Pharmaceutical Association, Seattle 2004 March 29, 2004.

Hartzema AG, Uphold C, Kwon S-Y, Stevens G. Adherence as predictor of treatment outcome in HIV infected men. VA R & D National meeting, W-DC March 9-12, 2004.

Mehta SR, Mayhew DY, DeLeon JM, Boyette RL, **Hartzema AG**, Lottenberg R. The health care transition (HCT) process for young adults with sickle cell disease (SCD): A qualitative assessment. American Society for Hematology. Dec 6, 2003.

Hartzema AG, Winterstein AG, Kwon S-Y. A Cost-benefit model for perindopril in secondary stroke prevention. ISPOR Sixth International Conference, podium presentation, Barcelona Nov 10, 2003²

Kwon, S-Y, **Hartzema AG**, Dunkin P. Disability in stroke outcomes research: clinical meaning of the Barthel Index, the Functional Independence Measure and the Modified Rankin Scale. ISPOR Sixth International Conference, Poster presentation, Barcelona Nov 11, 2003.

Kwon S-Y, MD Taylor, D Mayhew, **Hartzema AG**. Cost source and perspective in economic outcomes studies: focus on posters presented at 7th annual international ISPOR meeting. ISPOR Barcelona Nov 11, 2003.

Hartzema AG (Chair). Zinah I, Strom B, Lawless G, Harkarson H. Symposium Pharmacogenomics in the risk management paradigm. The 19 International Conference of Pharmacoepidemiology, August 19, Philadelphia

Hartzema AG. Johnson MR. Ethnic differences in the utility of a primary care panic screening instrument. The 19 International Conference of Pharmacoepidemiology, August 19, Philadelphia

Kwon, S-Y, **Hartzema AG**, Duncan PW, Min Lai, S. Measuring disability in stroke outcomes research. The clinical meaning of the Barthel Index, the Functional Independence Measure and the Modified Rankin Scale. The 19 International Conference of Pharmacoepidemiology, August 19, Philadelphia

Richardson L, **Hartzema AG**, Voti L, McKinnon J, Fleming LE, Trapido E.. Chemotherapy for Regional Stage Breast Cancer in Florida. Annual Conference of the North American Association of Central Cancer Registries. Honolulu, Hawaii, June 8-12, 2003.

Richardson L, **Hartzema AG**, Fleming L, MacKinnon J, Voti L. Chemotherapy for regional breast cancer in Florida: Role of insurance.

²**Hartzema AG**, Winterstein AG, Kwon SY. A Cost-Benefit model for perindopril in secondary stroke prevention. ISPOR Washington DC May 20, 2003

Hartzema AG. The Economic Burden of Actinic Keratosis. ISPOR Washington DC May 19, 2003

Hartzema AG, Johns T, Winterstein AG. Patient safety; medication error prevention in critical access hospitals. Florida's Rural Health Summit: Securing Health for Florida, Gainesville May 6, 2003

Johnson MR, Mills TL, De Leon JM, **Hartzema AG**, J. Haddad J, Christensen R. Lives in Isolation: Stories and Stuggles of Low-income African American Women Experiencing Panic Disorder. UF Medical College Research Day, April 19, 2003.³

De Leon JM, Johnson MR, **Hartzema AG**, Mills TL, Haddad J, Christensen R. Low-income Latinas with Panic Disorder: Barriers to Care within Social and Provider Networks. UF Medical College Research Day, April 19, 2003.³

Johnson MR, JM De Leon, TL Mills, **AG Hartzema**, J Haddad and R Christensen. Low-income Primary Care Patients with Panic Disorder: Cultural Differences in Barriers to and Preferences for Treatment. UF Medical College Research Day, April 19, 2003.

Johnson MR, **AG Hartzema**, JM De Leon and TL Mills. Ethnic Differences in the Utility of a Primary Care Panic Screening Instrument. UF Medical College Research Day, April 19, 2003.

Johnson MR, **AG Hartzema**, M. Yang, TL Mills, JM De Leon, G. Tod-Houston, W Bailey, S Witman, D Nelson, C Freuh, K Magruder and A Santos. Under-recognition of Psychiatric Disorders and Psychological Symptoms in Low-income African American Primary Care Patients. UF Medical College Research Day, April 19, 2003.

Johnson MR, Christensen R, DeLeon J, **Hartzema AG**, Mills TL, Haddad J. The use of qualitative methods to guide the development of treatment programs for low-income African American women with panic attack disorder. Anxiety Disorders Association of America, Toronto March 23, 2003.

DeLeon JM, Johnson MR, **Hartzema AG**, Mills TL. Low-income Latinas with Panic Disorder: Barriers to care within social and provider networks. Anxiety Disorders Association of America, Toronto March 23, 2003.

Johnson MR, **Hartzema AG**, Christensen R, DeLeon J, , Mills TL, Haddad J. Differences in the Utility of a Primary Care Panic Screening Instrument. Anxiety Disorders Association of America, Toronto March 23, 2003.

Mills TL, DeLeon JM, Johnson MR, **Hartzema AG**. Lives in Isolation: Stories and Struggles of Low-income African American Women Experiencing Panic Disorder Anxiety Disorders Association of America, Toronto March 23, 2003.

Johnson MR, Christensen R, DeLeon J, **Hartzema AG**, Mills TL, Haddad J. Low-Income Primary Care Patients with Panic Disorder: Cultural Differences in Barriers to and Preferences for Treatment, Anxiety Disorders Association of America, Toronto March 23, 2003.

DeLeon JM, Johnson MR, **Hartzema AG**, Mills TL¹. Low-income Latinas with Panic Disorder: Barriers to care within social and provider networks. University of Florida, Women's Health Research Day, March 20, 2003.

Richardson L, **Hartzema AG**, Fleming L, MacKinnon J, Voti L. Chemotherapy for regional breast cancer in Florida: role of insurance. Submitted ASCO 2003.

Hartzema AG. A cost utility analysis of the treatment of Hepatitis B with Lamivudine as compared to Alpha Interferon and no treatment. FAPA Seoul October 5, 2002

Hartzema AG. The economic burden of illness of actinic keratosis FAPA Seoul October 5, 2002

Hartzema AG, Morse L. The Empowerment of Pharmacogenomics by Pharmacoepidemiology, Symposium, ISPE, August 20, 2002, Edinburgh

Kwon S, **Hartzema AG**. Cost-benefit analysis of Almotriptan from a societal perspective using clinical trial outcomes. ISPOR 7th Annual International Meeting, Summer 2002. (Accepted May 21, 2002 Crystal City, Arlington.)

Hartzema AG. Granting foundations: an end user's perspective in the Symposium on "Research funding from private foundations" at the American Pharmaceutical Association meeting March 16, 2002, Philadelphia (invited).

Kwon, Soo-Yeon, **Hartzema AG**. A Cost-benefit analysis of Almotriptan compared to Sumatriptan for the treatment of migraine. Poster presentation at the American Pharmaceutical Association meeting. March 17, 2002 Philadelphia.

Hartzema AG, Dow W. Economic burden of Actinic Keratosis and Squamous cell carcinoma. Efficacy, Safety, and Cost of Office-Based Surgery: An NIH -Sponsored Conference at Graylyn International Conference Center at Wake Forest University., Winston-Salem. January 19, 20002. (Invited)

Siega-Riz AM, Cogswell EM, **Hartzema AG**. A trial of selective versus routine iron supplementation to prevent third trimester anemia during pregnancy. Society for Maternal-Fetal Medicine. 2002 Annual meeting, New Orleans, Jan 17, 2002.

Hartzema AG, Dow WH, Pangastuti HP, Shatin DS, Manda BS. Economic burden of Actinic Keratosis and Squamous Cell Carcinoma in ambulatory care. American Society of Clinical Oncology 37th ASCO Annual Meeting, San Francisco, May 13, 2001.

Siega-Riz AM, **Hartzema AG**, Jasti S. Differences in women's perceptions of anemia and supplement use during pregnancy by level of compliance. ISLI Health Promotion Conference on Forging Effective Strategies to Combat iron Deficiency.

Jasti S, Siega-Riz AM, **Hartzema AG**. Reasons for poor and good compliance with prenatal supplements. ISLI Health Promotion Conference on Forging Effective Strategies to Combat iron Deficiency.

Jasti S, Siega-Riz AM, **Hartzema AG**. Socio-demographic determinants of compliance with prenatal supplements among pregnant women. International Nutrition Conference, Vienna, August 2001.

Hartzema AG. IX Russian Symposium " Drug and Man" Practical Applications of Pharmacoepidemiological Data. Moscow, April 11, 2002

Hartzema AG. IX Russian Symposium "Drug and Man" Cost/effectiveness of Lamivudine in the treatment of Chronic Hepatitis B. Moscow, April 11, 2002

Hartzema AG. FFM Advanced Pharmacoeconomic Theories. Jakarta Indonesia , August 4, 2002

Hartzema AG. Indonesian Pharmacist Association. Cost-Effectiveness Analysis and Hr-QL. Jakarta Indonesia, August 2, 2001

Hartzema AG, Siega-Riz AM, Cogswell EM. Validation of compliance in a RTC of iron supplementation in pregnant women. American Pharmaceutical Association. San Francisco, 2001.

VonScheele B, **Hartzema AG**, Biddle A. Cost-effectiveness of Carbotocin compared to Oxytoc for the prevention of uterine atony after a cesarean section. American Public Health Association, Boston, Nov 14, 2000

Hartzema AG, Winterstein AG. QualIPharm “Value by Pharmacist” project. FIP Value by Pharmacist symposium, Vienna September 6, 2000.

Hartzema AG, Day RS, Sleath B, Tolleson-Rinehart S, Bush PJ. Designing written drug information to enhance patients comprehension and recall. The 11th International Social Pharmacy Workshop “Past and Future of Social Pharmacy”, Kuopio Finland, June 16, 2000

Hartzema AG, Shih YCT, Tolleson-Rinehart S, Gorospe J, Goldfarb S. Costing the care for urinary incontinent patients in long-term care facilities. The 11th International Social Pharmacy Workshop “Past and Future of Social Pharmacy”, Kuopio Finland, June 15, 2000

Hartzema AG, Isacson D. (Co-Chairs) Epidemiological models in Quality Indicator development, The 11th International Social Pharmacy Workshop “Past and Future of Social Pharmacy”, Kuopio Finland, June 15, 2000

Shih YCT, **Hartzema AG**, Tolleson-Rinehart S, Gorospe J, Goldfarb S. Costing the care for urinary incontinent patients in long-term care facilities. Society for Medical Decision Making, 1999.

Hartzema AG. Comprehension and recall in written drug information. FIP World Congress of Pharmacy and Pharmaceutical Sciences '99, Barcelona Sept 9, 1999

Clark T, Shih YCT, Dupuis B, **Hartzema AG**. The cost-effectiveness of immunosuppressive therapy after renal transplantation. ISPOR, Crystal City May 25, 1999 (contributed poster).

Hartzema AG, Day, RS, Tolleson-Rinehart, S. Optimizing patient comprehension through medicine information leaflets. Staff Seminar at USP-DI. Rockville, May 25, 1999.

Hartzema AG, Effectiveness and cost-effectiveness considerations in drug treatment. Royal Society of Surgeons and Physicians, 400 Year celebration, Glasgow, Scotland, April 23, 1999.

Hartzema AG, Economic considerations in the treatment of Uncomplicated Urinary tract Infection. Icelandic University School of Public Health, Redjavik April 19, 1999.

Hartzema AG, Kauf T, Huang, X, Norwood J, Raasch R. Outcomes of UTI treatment in a NC Medicaid Administration (Poster). Challenges in Geriatric practice, Conference organized by UNC Medical School Program on Aging, Friday Center UNC, January 15-16, 1998.

Hartzema AG, Australasian Pharmaceutical Science Association (APSA) conference Plenary presentation: Pharmaceutical Outcomes Research, Sydney Australia, November 28, 1997.

Hartzema AG. Seminar: “Experimental versus observational methods in evidence-based prescribing” University of Otago, School of Pharmacy, New Zealand, Nov 24, 1997

Hartzema AG. Pharmacoeconomics and Prescribing guidelines: Uncomplicated urinary tract infection as a case example, World Congress of Pharmacy and Pharmaceutical Sciences '97, 57th International Congress of FIP, Vancouver September 3, 1997

Hartzema AG. Introductory Speech: Academic Cooperation, Doctor of Philosophy Program in Pharmacy Administration between School of Pharmacy, The University of North Carolina at Chapel Hill, and College of Pharmacy, University of Arizona and Faculty of Pharmacy, Mahidol University, Novotel Hotel, Bangkok, March 31, 1997.

Hartzema AG. Clinical and Cost Outcomes in the Treatment of Uncomplicated Urinary Tract Infection. Faculty of Pharmacy, Mahidol University, Bangkok, Thailand, March 31, 1997.

Hartzema AG. Application of Pharmacoepidemiology in Hospital Pharmacy Management, Prince of Songkla University, Hat Yai, Thailand, March 27, 1997.

Hartzema AG. Trends of Outcomes Research. College of Public Health. Chulalonghorn University, Bangkok, Thailand, March 24, 1997.

Hartzema, AG, Chair, Roundtable Session: New uses of pharmacologic data/new directions in disease management: Quality of Care: New Initiatives, Partnerships, and Technology. 11th Annual Symposium of the Center for Clinical Quality Evaluation, Arlington, VA, Nov 1996.

Hartzema, AG, Pharmacologic Outcomes Management. Quality of Care, New Incentives, Partnerships and Technology. 11th Annual Symposium of the Center for Clinical Quality Evaluation, Arlington, VA, Nov 1996.

Hartzema AG, Pharmacoepidemiology: an international perspective. 2nd Pharmacoepidemiology conference organized by CEFAR, Lisbon, Portugal, Oct 1996.

Hartzema, AG, Drug Information Provisions for Children. World Congress of Pharmacy '96, Jerusalem, Israel, Sept 1996.

Hartzema, AG, Disease State Management. Sixth International Public Health Pharmacy Issues Conference, Jerusalem, Israel, Sept 1996.

Hartzema, AG, Improving quality of pharmaceutical care in nursing homes; what research is needed? Social Pharmacy Workshop, University of Wisconsin, Madison, August 13, 1996.

Hartzema, AG, Day, R et al. How common is “common”, how rare is “rare”? Social Pharmacy Workshop, University of Wisconsin, Madison. August 12, 1996.

West, SL, Savitz G, Koch G, Thorn BL, Guess H, **Hartzema AG,** Demographics, health behaviors and past drug use as determinants of recall accuracy for previous medications, ISPE Montreal Canada, August 30, 1995.

Hartzema, AG, Outcome measurement issues as related to pharmacotherapeutic interventions. Program on Aging Lecture Series. Medical School MacNider Jan 18, 1995

Hartzema, AG. Pharmacists' Role and Quality of Life. 15th Asian Congress of Pharmaceutical Sciences. Federation of Asian Pharmaceutical Associations. November 15, 1994. Bangkok Thailand.

Hartzema, AG. Teaching therapeutic reasoning through the case-study approach: adding the probabilistic dimension. AACP 95th Annual Meeting. July 20, 1994, Albuquerque, New Mexico.

Hartzema, AG. Operationalization of constructs. Eighth International Workshop of Social Pharmacy, July 7, 1994. Berlin, Germany.

Perfetto, EM, Baldwin R, Konrad TR, Sloane PD, **Hartzema AG.** Drug utilization review: A measure of prescriber decision making or state Medicaid program policy? GSA. 46th Annual Scientific Meeting, Nov. 20, 1993. New Orleans.

Perfetto, EM, Baldwin, R, Konrad, TR, Sloane, PD, Koch, G, **Hartzema, AG**. DUR and appropriate drug prescribing: effects on board and care resident outcomes. GSA. 46th Annual Scientific Meeting, November 20, 1993, New Orleans.

Hartzema, AG. Quality of Life Evaluations, Mahidol University, Bangkok, November 18, 1993. Invited.

Hartzema, AG. Methods in Pharmacoepidemiology, Chulalongkorn University, November 18, 1993. Invited.

Hartzema, AG. Pharmacoepidemiology in relationship to rational drug use. Thai FDA, Bangkok, November 17, 1993. Invited.

Hartzema, AG. Researchers in Pharmacoepidemiology, Khon Kaen University, Khon Kaen, November 16, 1993. Invited.

Hartzema, AG. Pharmacoepidemiology and Pharmacy Practice, Northeastern Pharmacist Annual Meeting 1993, Nong Kai, November 12, 1993. Invited.

Hartzema, AG. Pharmacoepidemiology with applications to Clinical Pharmacy. Prince of Songkla University, Hat-Yai, November 9, 1993. Invited.

Hartzema, AG. Pharmacoepidemiology, Outcomes Research and Quality of Life, Socio-economic pharmacy seminar, sponsored by Institute Sains Dan Teknologi National (ISTN), Sahid Gawa Hotel, Jakarta, September 21, 1993. Invited.

Hartzema, AG. Pharmacoepidemiology in Public Health, Department of Pharmacy, University of Jakarta, September 20, 1993. Invited.

Hartzema, AG. Clinical aspects of pharmacoepidemiology, Faculty of Pharmacy Airlangga University, Surabaya, September 16, 1993. Invited.

Hartzema, AG. Socio-economic aspects of pharmacoepidemiology, Faculty of Pharmacy, Gajah Mada University, Yogyakarta, September 15, 1993. Invited.

Hartzema, AG. Quality of Life Measures: Use of Construct Variables in Outcome Evaluations. Institute Teknologi Banderung (ITB), Bandung, West Java, September 14, 1993. Invited.

Hartzema, AG. Teaching of Administrative Pharmacy in the U.S., Institut Sains Dan Teknologi National (ISTN), Pharmacy Department, Jakarta, September 13, 1993. Invited.

Hartzema, AG. Pharmacoepidemiology as a basis of pharmacoeconomic analysis. Third International Conference on Public Health Issues, Tokyo, Japan, September 5, 1993. Invited.

Hartzema, AG. Pharmacoepidemiology in the context of outcomes research. Annual meeting of the International Society of Pharmacoepidemiology, Washington, DC, August 29, 1993.

Hartzema AG. The patient consultation mandate: Implications for management education and experiential training. The patient consultation mandate: unresolved issues and viewpoints. Section of teachers of pharmacy administration. American Association of Colleges of Pharmacy. 99th Annual Meeting. San Diego, July 11, 1993.

Hartzema AG. Biotechnology: Patient Outcomes and Costs Impacts, an example in case: the trials and tribulations of HA-1A. Blue Cross & Blue Shield, Durham, NC, March 2, 1993.

Almarsdottir AB, Hick S, **Hartzema AG**, Bush PJ. Drugs kept in households with children. American Pharmaceutical Association, Washington, DC, March 21, 1993.

Hartzema AG, Cash T, Mabie J, Cortez A. An evaluation of pharmaceutical services in a random sample of North Carolina Family Care Homes. American Pharmaceutical Association, Washington, DC, March 21, 1993.

Hartzema AG. Use of construct variables in outcome evaluations: Quality of life measures. Graduate Student Seminar, Purdue University, October 9, 1992.

Baldwin R, Perfetto EM, Murphy T, **Hartzema, AG**, Burnham L. Medication administration errors in Board and Care Homes, American Pharmaceutical Association, Washington, DC, March 9, 1992.

Murphy AT, Hogue CC, Baldwin R, **Hartzema AG**. The relationship between person, environment, and health outcomes in the domiciliary care facility. 45th Annual Meeting of the American Gerontological Society of America, Washington, DC, November 18-22, 1992.

Hartzema AG. Pharmacoepidemiology and its contributions to our drug knowledge. State Institute for Drug Control and Department of Hygiene, Charles University, Prague, Czechoslovakia, September 7, 1992.

Hartzema AG, Almarsdottir A, Bush P. Children and Medicine Use. EEC-COMAC project: The American Experience, 2nd International Public Health Pharmacy Issues Conference, Paris, France, Sept 11, 1992 Invited. (Chairman)

Hartzema AG, Impact of an aging population on the demand for pharmaceutical services, Pharmacy World Congress 1992 and 52nd International Congress of FTP, Lyon France, Sept 15, 1992 Invited.

Hartzema AG, Sepsis epidemiology and treatment outcomes. Social Pharmacy Workshop, University of London, July 20, 1992, Edgan, Great Britain

Hartzema, AG, Outcomes Research in Pharmaceutical Care. Research in Pharmaceutical Care, AACP Annual Meeting, July 12, 1992 Washington, D.C. Invited.

Hartzema, AG, Drug Therapy Management in Resthomes, Economic, Social and Administrative Sciences Extended Paper Session, American Pharmaceutical Association, March 16, 1992, San Diego. Invited.

Hartzema AG, Sloane PD, Rizzolo, PJ, Koch GC. Strengthening the Links in the Drug Therapy Management Cycle in Rest Homes; the Physician Intervention. Forty-fourth Annual Scientific Meeting, Gerontology Society of America, November 22-26, 1991, San Francisco.

Perfetto EM, **Hartzema AG**, Sloane PD, Konrad TR. Rest Home Physicians' Assessment of Their Continuing Education Needs. Forty-fourth Annual Scientific Meeting, Gerontology Society of America, November 22-26, 1991, San Francisco. Invited.

Baldwin R, **Hartzema AG**. Organizational Factors Affecting Drug Use in Long-term Care. Forty-fourth Annual Scientific Meeting, Gerontology Society of America, November 22-26, 1991, San Francisco.

Hartzema, AG. Pharmacotherapy and Drug Outcomes in Older Populations, Second International Searle Symposium on Prevention and Epidemiology, October 7-9, 1991, Chapel Hill, NC.

Hartzema AG, Grabenstein J. Pharmacists as Immunization Advocates. Social Pharmacy, Biomedicum, University of Uppsala, Sweden, May 24, 1991 (Invited.)

Hartzema AG. Pharmacoepidemiology: State-of-the art, Symposium Swedish Academy of Pharmaceutical Sciences, Stockholm, Sweden, May 23, 1991 (Invited Keynote Speech).

Hartzema AG. Quality of Life Measures: Methodological Considerations, Symposium Swedish Academy of Pharmaceutical Sciences, Stockholm, Sweden, May 23, 1991 (Invited).

Hartzema AG. Perspectives on Pharmacoepidemiology. First World Conference of Portuguese Speaking Pharmacists, Lisbon, Portugal, May 17, 1991. (Invited Keynote Speech).

Perfetto EM, Murphy T, Baldwin R, **Hartzema AG.** Strengthening the Links in the Drug Therapy Management Cycle in Resthomes: A Communication Initiative. National Council for Patient Counseling and Education, Washington DC, April 22, 1991.

Hartzema AG. Medication Use in Long-Term Care Facilities, Program on Aging, School of Medicine, March 20, 1991.

Hartzema, AG. New Directions in Postmarketing Surveillance, presented at a symposium sponsored by Roerig/Pfiser, December 1, 1990, Las Vegas, Nevada.

Baldwin R, Perfetto EM, Murphy T, **Hartzema AG**, Burnham L. Medication Administration Errors in Board and Care Homes. APHA Meeting, New Orleans, March 9, 1991.

Hartzema AG. Chaired symposium. Board and Care Facilities: Not Just Little Nursing Homes. Presented: Differences in the Organization of Pharmaceutical Care Between Board and Care Facilities and Nursing Homes, 43rd Annual Scientific Meeting, Gerontology Society of America, Boston, November 16, 1990.

Sloane PD, Baldwin R, Burnham L, **Hartzema AG**, Perfetto EM and Rizzolo P. Physician prescribing in North Carolina Rest Homes. 43rd Annual Scientific Meeting "Generations: Continuities, Conflicts and Reciprocities, Gerontology Society of America, Boston 11-17-1990.

Hartzema, AG. The Role of Pharmacoepidemiology in Clinical Pharmacy, presented at the 19th European Symposium of Clinical Pharmacy, Barcelona Spain, October 25, 1990 (Invited.)

Hartzema, AG. Outcome Measurements in Pharmacoepidemiological Intervention Studies. American Public Health Association Annual Meeting, New York, NY, September 30, 1990.

Hartzema AG. Pharmacoepidemiological Impacts in Managerial Decision Making, presented at the 50th International Congress of F.I.P., Istanbul, Turkey, September 6, 1990 (Invited).

Hartzema AG. Criteria for the Evaluation of the Scientific Literature. Main Symposium, 50th International Congress of F.I.P., Istanbul, Turkey, September 5, 1990 (Invited).

Hartzema AG. Outcome Measures in Rest Homes. School of Pharmacy, Queen's University, Belfast, Northern Ireland, June 27, 1990.

Hartzema AG. Methodological Considerations in Evaluating Outcomes, Social Pharmacy Workshop, Geiranger, Norway, June 4, 1990.

Hartzema AG. Outcome Measures in Geriatric Interventions, University of Linköping, Sweden, May 30, 1990.

Hartzema, AG. Outcome Measures in Rest Homes, School of Pharmacy, University of Kuopio, Finland, May 15, 1990.

Hartzema AG. Pharmacoepidemiology of Antitrombolytics, Department of Clinical Pharmacology, Karolinska Institute, Stockholm, Sweden, March 23, 1990 (Invited).

Hartzema AG. Quality of Life and Cost Effectiveness Outcomes, University of Uppsala, Sweden, March 15, 1990.

Perfetto EM, Baldwin R, **Hartzema AG**, McLeod D. Use of Pharmacoepidemiologic Methods: A Comparison of Two Thrombolytic Drugs. APhA Annual Meeting, Washington, DC, March 11, 1990.

McLeod D, **Hartzema AG.** Pharmacoepidemiology of Bleeding Events After Use of Alteplase or Streptokinase for Acute Myocardial Infarction, Annual Meeting, California Society of Hospital Pharmacists, Anaheim, CA, October 29, 1989.

McLeod D, **Hartzema AG.** Pharmacoepidemiology of Bleeding Events After Use of Alteplase or Streptokinase for Acute Myocardial Infarction, Annual Meeting, European Society of Clinical Pharmacy, Nijmegen, The Netherlands, October 27, 1989.

Hartzema AG, McLeod DC, et al. Bleeding Events and Thrombolytic Therapy. Seminar '89 - Future Horizons, Annual Meeting of the California Society of Hospital Pharmacists. October 26-29, 1989.

Hartzema AG, Perfetto EM. Supply of Pharmaceutical Scientists and the Relative Rate of Return: Retail Pharmacist vs. Faculty. (poster) 4th Annual Meeting of the American Association of Pharmaceutical Scientists, October 23, 1989, Atlanta, Georgia.

Hartzema AG. "Challenges of 1992 for the International Pharmaceutical Industry", (Post-graduate course for managers of the European Pharmaceutical Industry). Institute of Postgraduate Business Education, September 11, 1989, Zeist, The Netherlands.

McLeod D, **Hartzema AG.** Methodologic Concerns in the Pharmacoepidemiology of Bleeding Events After Thrombolytic Therapy and Acute Myocardial Infarction. Fifth Annual International Conference on Pharmacoepidemiology. University of Minnesota, Minneapolis, September 5-8, 1989.

Hartzema AG. "The Drug Approval Process in 1992: How Will it Look?", 49th International Congress of the International Pharmaceutical Federation, September 4-9, 1989, Munich, Germany.

Hartzema AG. Clinical Epidemiology for the Pharmaceutical Industry, Problems and Pitfalls in Measuring Drug Exposure, July 12, 1989, Chapel Hill, NC. (Invited).

Hartzema AG, O'Brien LP. Medication Noncompliance: A Didactic Exercise. (poster) American Association of Colleges of Pharmacy/Association of Faculties of Pharmacy of Canada Annual Meeting, July 11, 1989, Portland, OR.

Hartzema AG. Pharmacoepidemiology: An Evolving Opportunity for Pharmacists - Discuss the how, when and where of introducing the subject into a College of Pharmacy's curriculum. American Association of Colleges of Pharmacy/Association of Faculties of Pharmacy of Canada Annual Meeting, July 11, 1989, Portland, OR. (Invited)

Hartzema AG, McLeod D, Importance of Pharmacoepidemiology in Hospital and Clinical Pharmacy. Winter Meeting, N.C. Society of Hospital Pharmacists, High Point, NC, February 2-3, 1989.

Hartzema AG, McLeod DC. Pharmacist Involvement in Pharmacoepidemiologic Studies, 1989 Annual Winter Meeting, North Carolina Society of Hospital Pharmacists, February 2, 1989, High Point, NC. (C.E.)

Hartzema AG, Temple DJ, Wertheimer AI. The role of schools of pharmacy as providers of continuing education: results of a worldwide survey. Symposium on university involvement in postgraduate studies,

Academic Section, Federation Internationale Pharmaceutique, Sydney, Australia, September 8, 1988.
(Invited)

Hartzema AG. Pharmaceutical services in homes for the aged, PSANZ Conference, September 4, 1988, Sydney, Australia.

Hartzema AG. Computers in Pharmacy, April 27, 1988, Burlington, NC. (C.E.); July 17, 1988, Eden, NC. (C.E.); September 11, 1988, Greensboro, NC. (C.E.)

Hartzema AG, Presider. Session entitled "Public Drug Insurance Programs for the Elderly: Implications for Community Pharmacy". Annual Meeting of the American Pharmaceutical Association, March 14, 1988, Atlanta, Georgia. (Invited)

Hartzema AG. Interventions to improve drug therapy management in homes for the aged, Symposium on drug treatment in the elderly, Swedish Academy of Pharmaceutical Sciences, Stockholm, Sweden, November 4-6, 1987. (Invited)

Hartzema AG. Education in Pharmacy Administration at the University of North Carolina at Chapel Hill, and Prescription Drug use in the Elderly. Both presented at Norsk Medicinal Department, Oslo, Norway, November 2, 1987. (Invited)

Hartzema AG. Physician Prescribing Influences in Managed Health Care." HMO Workshop, sponsored by Janssen Pharmaceuticals and Triclinica, Scottsdale, Arizona, October 18-20, 1987. (Invited)

Hartzema AG, Blom, L. Quality of clinical education, F.I.P. symposium: Quality control in hospital pharmacy, University of Leyden, Leyden, Holland, September 6, 1987. (Invited)

Hartzema AG. Drug administration decisions by lay caregivers using locus of control as an explanatory variable, 47th International Congress of Pharmaceutical Sciences of F.I.P., Amsterdam, Holland, September 2, 1987.

Hartzema AG and Phillips JH. Mail-order Pharmacy Usage Pattern in a Veteran Population, American Pharmaceutical Association, March 31, 1987, Chicago, IL.

Hartzema AG. Selecting a pharmacy computer system, February 23, 1987, Central Carolina Hospital, Sanford, NC. (C.E.)

Hartzema AG. Evaluating Pharmacy Services in Domiciliary Care Facilities, University of Southern California, Los Angeles, CA, February 9, 1987. (Invited)

Freund DA, **Hartzema AG,** and Lee S. The economic impact of compliance, Medical Care Section, 114th Annual Meeting of the American Public Health Association, Las Vegas, Nevada, October 1, 1986. (Invited)

Hartzema AG, Lee RH, Konrad TR, and Sawyer WT. Targeting clinical pharmacy services using aggregate DRG cost data, Medical Care Section, 114th Annual Meeting of the American Public Health Association, Las Vegas, Nevada, September 29, 1986.

Hartzema AG. Drug information management and provision skills taught to pharmacy students: an international perspective. Presented at the Symposium "Standards and Criteria of Pharmacy Education necessary for the Practice of Profession." 46th F.I.P Congress, September 1-5, 1986, Helsinki, Finland. (Invited)

Hartzema AG. Strengthening the links in drug therapy management cycle in homes for the aged, Fourth International Social Pharmacy Workshop, September 8-10, 1986, Stockholm, Sweden. (invited)

Hartzema AG. Pharmacoepidemiology of psychotropic use by the mentally ill in longterm care facilities, Nathan S. Kline Institute for Psychiatric Research, June 12, 1986, Orangeburg, NY. (invited)

Hartzema AG, McCollum G. Assessing spouse's support in drug compliance, American Pharmaceutical Association, March 19, 1986, San Francisco, CA.

Hartzema AG, Habib K. A social support strategy to improve compliance in an arthritis population, American Public Health Association, November 18, 1985, Washington, DC.

Notaro J, **Hartzema AG.** An overview of pharmaceutical assistance programs, American Public Health Association, November 20, 1985, Washington, DC.

Hartzema AG. Computers in pharmacy, September 10, 1985, AHEC, Wilmington, NC (C.E.).

Hartzema AG. Capitation reimbursement for pharmacy services. Sixth International Conference on Pharmacy Economics, September 1-2, 1985, Montreal, Canada (Invited).

Hartzema AG. The role of pharmacy administration in the education of Pharm.D.'s, panel presentation and discussion, Southeast Regional meeting of pharmacy administration faculty, May 17, 1985, Chapel Hill, NC (Invited).

Hartzema AG. Getting more out of your pharmacy computer, April 18, 1985, AHEC, Hickory, NC (C.E.).

Hartzema AG. Computer literacy, April 17, 1985, AHEC, Hickory, NC (C.E.).

Hartzema AG. Getting more out of your pharmacy computer, April 4, 1985, AHEC, Winston-Salem, NC (C.E.).

Hartzema AG. Computer literacy, April 3, 1985, AHEC, Winston-Salem, NC.

Hartzema AG, Gagnon JP and Habib K. Refill counts as a proxy measure for compliance behavior: methodological considerations, Academy of Pharmaceutical Sciences, 132nd American Pharmaceutical Association Annual Meeting, February 20, 1985, San Antonio, TX.

Hartzema AG, McDermott JH. Drug prescribing frequencies in extended care facilities, Academy of Pharmaceutical Sciences, 132nd American Pharmaceutical Association Annual Meeting, February 19, 1985, San Antonio, TX.

Hartzema AG. Determinants of medication compliance in a V.A. arthritis population, Arthritis Health Professions Fellows Conference, November 30 - December 2, 1984, Amelia Island Plantation, FL (Invited).

Gagnon JP, **Hartzema AG,** Mackowiak JI and Thomas III J. Financial management seminar, North Carolina Mutual Wholesale Drug Company, October 29, 1984, Durham, NC (C.E.).

Hartzema AG and Capowski CW. Drug information provisions in case of emergency by elderly in independent living arrangements, International Congress of F.I.P., September 3-7, 1984, Budapest, Hungary.

Hartzema AG. The teaching of social and administrative pharmacy in clinical pharmacy curricula, 49th International Congress of F.I.P., September 3-7, 1984, Budapest, Hungary.

Hartzema AG and Gagnon JP. The ontogeny and phylogeny of Pharm.D. graduates' employment characteristics, Innovations in Academia, Annual Meeting of the American Association of Colleges of Pharmacy, July 29-August 1, 1984, Baltimore, MD.

Lockridge RV and **Hartzema AG**. The elderly -- falls and medication: is there a correlation?, 15th Annual Southeastern Conference for Post-Graduate Pharmacy Education and Training, March 9-11, 1984, Athens, GA.

Hartzema AG. Geographic distribution and role development of clinical pharmacists, Annual Meeting of the American Public Health Association, November 13-17, 1983, Dallas, TX.

Hartzema AG. Social roles and psychological predispositions affecting self-medication pattern, Swedish Academy of Pharmaceutical Sciences, Symposium on Self-Medication, November 9-11, 1983, Stockholm, Sweden (Invited).

Hartzema AG. The use of measurement instruments in evaluating drug therapy outcomes, Gorlaeus Laboratorium, Ryksuniversiteit Leyden, November 8, 1983, Leyden, The Netherlands (Invited).

Hartzema AG. An epidemiological framework for dispensing decision making by potential drug-drug interactions, F.I.P. 43rd International Congress of Pharmaceutical Sciences, September 5-9, 1983, Montreux, Switzerland.

Hartzema AG. Drug prescribing as a function of physician-patient interaction, F.I.P. 43rd International Congress of Pharmaceutical Sciences, September 5-9, 1983, Montreux, Switzerland.

Hartzema AG. Computer literacy for pharmacy practitioners, Continuing Education Program, University of North Carolina at Chapel Hill, August 17, 24-25, 1983, Chapel Hill, NC.

Hartzema AG. Research Seminar, Clinical Epidemiology and Health Services Research, Veterans' Administration Medical Center, June 17, 1983, Durham, NC.

Hartzema AG and Gagnon JP. Computer-assisted financial analysis program for community pharmacists as a tool for continuing education, Annual Meeting of the American Association of Colleges of Pharmacy, June 13-17, 1983, Washington, DC.

Gagnon JP and **Hartzema AG**. Improving verbal and written skills among pharmacy students, Annual Meeting of the American Association of Colleges of Pharmacy, June 13-17, 1983, Washington, DC.

Hartzema AG and Montagne M. Differential emphasis in social pharmacy programs: a cross-national analysis of historical development, Annual Meeting of the American Association of Colleges of Pharmacy, Section of Teachers of Pharmacy Administration, June 30, 1982, Kansas City, MO.

Osterhaus JT, Jang R, **Hartzema AG**. A comparison of terminal and professional values of pharmacy students with four reference groups, Annual Meeting of the American Association of Colleges of Pharmacy, Section of Teachers of Pharmacy Administration, June 30, 1982, Kansas City, MO.

Hartzema AG. A model of the utilization of prescription drug knowledge, 18th Annual Meeting of the Drug Information Association, June 13, 1982, Kansas City, MO.

Hartzema AG. The impact of selected illness behaviors in delay in seeking professional care for rheumatoid arthritis, 129th Annual Meeting of the American Pharmaceutical Association, April 25-29, 1982, Las Vegas, NV.

Hartzema AG. Comparison of three different populations on their "expectancies" from self-medication vs. medical care, 41st Conference of the Federation Internationale de Pharmacia, September 5, 1981, Vienna, Austria.

Hartzema AG. When is the best medicine no medicine at all? Midwest Conference for the Society for Health and Human Values, May 3-5, 1981, Minneapolis, MN.

Hartzema AG. Illness behaviors related to delay in seeking medical care, Arthritis Foundation, Minneapolis Chapter, February 18 & 20, 1981, Minneapolis, MN.

Hartzema AG. The development of a multidimensional health locus of control scale for illness behaviors, Division of Pharmacy Administration, School of Pharmacy, University of North Carolina at Chapel Hill, November 4, 1980, Chapel Hill, NC.

Hartzema AG. The development of a multidimensional health locus of control scale for illness behaviors, Division of Administrative and Social Sciences in Pharmacy, College of Pharmacy, Ohio State University, October 30, 1980, Columbus, OH.

¹ First prize in the psycho-social health category and first prize in the faculty category for all posters, 2003

² Poster Finalist Award, International Society for Pharmacoeconomic Outcomes Research, 2003

³ Poster Finalist Award, International Society for Pharmacoeconomic Outcomes Research, 2004

⁴ New Investigators Award, International Society for Pharmacoeconomic Outcomes Research, 2005

Addendum I

DSMB Chair, Division of Thoracic and Cardiovascular Surgery, Shands Hospital at the University of Florida, January 10, 2008 – present.

DSMB Chair, Division of Nephrology, School of Medicine, Shands Hospital at the University of Florida, May 6, 2005 – December 10, 2007.